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ABSTRACT 
 
The risk of escape ovulation was investigated in women using a variety of low-dose 
combined oral contraceptives, under challenge in simulated conditions.  
 
Noncompliance was simulated by either lengthening the standard 7-day pill-free period by 
three days or until a follicle of predetermined size of 16 mm in diameter developed. Despite 
complete pituitary recovery by the end of the first pill-free week in most women, and variable 
degrees of ovarian activity, no ovulation was detected in 98 artificial cycles during or after the 
10-day pill-free period. However, follicular growth of ≥13 mm occurred in 53% of women and 
follicles became most developed in women using a monophasic desogestrel (DSG) pill 
containing 20 µg ethinylestradiol (EE2), compared with women on monophasic gestodene 
(GEST) (p=0.015) or triphasic GEST pills with no less than 30 µg of EE2 per day. It is 
concluded that escape ovulation is rare in women using GEST and DSG preparations 
containing as little as 20 µg of EE2 per day, when not more than the first three pills are 
omitted. Extending the pill-free period to 14 days, to allow a follicle to grow to 16 mm in 
diameter, on the other hand, led to ovulation in 4 of 5 women, despite restarting the pills 
(GEST 75 µg/EE2 20 µg).  
 
Mid-cycle charcoal treatment on three consecutive days did not alter the bioavailability of 
GEST or norethisterone (NET), as indicated by measurements of 24-h area under the curve 
(AUC0-24h), Cmax and tmax. Neither was ovulation detected after treatment with activated 
charcoal in 11 women using a combination of either 75 µg GEST or 1 mg norethisterone 
acetate (NET Ac), and 30 µg EE2. Hence, enterohepatic recirculation of GEST and NET does 
not seem to be of any clinical significance. This indicates that women using combined oral 
contraceptives can take activated charcoal for treatment of diarrhea, when administered 
three hours after pill intake at the earliest, and no later than 12 hours before the next pill. 
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I INTRODUCTION 
 
The initial prerequisite for development of combined oral contraceptives (OCs) was created 
far back in the 1930s, when the cybernetic mechanism of regulation between the 
hypothalamus, pituitary gland and the gonads was recognized (Hannse, 1987). 
Ethinylestradiol (EE2) was synthesized by Inhoffen in 1938 and the first synthetic 
progestogen, norethisterone, by Drejassi in 1951 (Hannse, 1987; Edgren, 1991). The first OC 
investigated in large-scale clinical trials was, however, a combination that contained 150 µg 
mestranol and 9.85 mg norethynodrel, marketed in 1960 as Enovid (Edgren, 1991). 
Norethynodrel has since vanished from the OC market, since in the early 1960s the 
conjugated form, norethisterone, showed its superiority (Cook et al., 1972; Edgren, 1991). 
The first OC containing EE2 (4 mg norethisterone acetate and 50 µg EE2) was introduced in 
1961 as Anovlar (Hannse, 1987).  
 
In an attempt to minimize the severe consequences of OCs, such as stroke, deep venous 
thrombosis and lung embolism, and post-pill amenorrhea, hormone doses have gradually 
been reduced, at first more successfully with regard to the estrogen component. The daily 
dose of EE2 has decreased over the years to 15 µg.  Along with the development of new, 
more potent progestogens, the dose of the progestogen component could also be reduced. 
In this thesis, regimens that contain a daily EE2  dose of 20-35 µg are referred to as "low-
dose" OCs, to differentiate them from older OCs containing 50 µg EE2, and from OCs with 
only 15 µg EE2, the latter being referred to as "ultra low-dose" OCs. 
 
Combined oral contraceptives exert their contraceptive action mainly through inhibition of 
ovulation via the suppression of gonadotropin levels. Whether this is modulated primarily at 
the hypothalamus or at the pituitary, is still not completely understood (Hemrika et al., 1993). 
The suppressive effect of the pill is dose-dependent (Dericks-Tan et al., 1976), and some 
residual ovarian activity has been demonstrated even with old-type pills containing 50 µg EE2 
(Elstein et al., 1974). However, the results of large clinical studies on OCs containing only 20 
µg of EE2 suggest almost no reduction in contraceptive efficacy (Endrikat et al., 1995; 
Endrikat et al., 1997; Endrikat et al., 2001; Rosenberg et al., 1999). In studies of low-dose 
OCs, in which ovarian function was determined, a variable degree of ovarian activity was 
measured, accompanied with almost no ovulation, when compliance was good (Coney and 
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DelConte, 1999; Crosignani et al., 1996; Fitzgerald et al., 1994; Killick et al., 1998; Spona et 
al., 1996a; Spona et al., 1996b; van Heusden and Fauser, 1999). In several studies 
demonstrating noncompliance with OCs containing 30 µg of EE2 or more, the results have 
been inconclusive. In addition, treatment groups have been small and few comparisons have 
been made between different regimens. Furthermore, neither prior to nor after the present 
study, has noncompliance been tested in women using OCs with less than 30 µg of EE2. 
 
While noncompliance is probably of the most importance, contraceptive efficacy of the pill 
may be influenced by any factor which interferes with circulating blood levels of exogenous 
estrogen or progestogen or with their action at the cellular level (Fraser and Jansen, 1983; 
Shenfield, 1986). Gastroenteritis has long been considered as a cause of malabsorption, with 
a consequent potential risk of pill failure (Adlercreutz et al., 1979; Hansen and Lundvall, 
1997; John and Jones, 1975; Sparrow 1998). A number of environmental factors may affect 
the serum concentrations of OC steroids, but evidence of the real clinical importance of any 
of the factors is scanty (Stadel et al., 1980).  
 
Concurrent medication may affect contraceptive efficacy by changing the pharmacokinetic 
pathways, affecting absorption and distribution of steroids in body tissues, their metabolism 
and transport in the circulation, and enterohepatic recirculation and excretion (Brodie and 
Feely, 1988). With regard to drug interactions and their role in pill failure, those due to 
induction of hepatic microsomal enzymes are well established (Back et al., 1980a; Crawford 
et al., 1990; Joshi et al., 1980a). In contrast, the association between broad-spectrum 
antibiotics and pill failure remains controversial. Such antibiotics may interfere with the 
enterohepatic circulation of exogenous steroids, thus lowering circulating blood steroid levels 
(Adlercreutz et al., 1979). However, enterohepatic circulation is thought to be relevant only for 
EE2, and few clinical studies have been carried out to investigate enterohepatic circulation 
and its clinical importance with regard to progestogens. 
 
The present study was aimed at elucidating some of the conflicting areas as regards the risk 
of escape ovulation under treatment with combined oral contraceptives, to allow us to provide 
fuller information to women using OCs.  
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II REVIEW OF THE LITERATURE 
 
1 MECHANISM OF ACTION OF OCS 
 
Although ovulation alone does not necessarily mean pill failure, inhibition of ovulation is 
considered to be a primary mechanism of the action of OCs. The mid-cycle surge of 
luteinizing hormone (LH) and follicle-stimulating hormone (FSH), as well as the preovulatory 
estradiol peak, believed to be the positive feedback mechanism for the release of 
gonadotropin-releasing hormone (GnRH), do not occur (Mishell et al., 1977). Whether this is 
regulated primarily at the hypothalamus or higher in the central nervous system by interfering 
with the pulsatile secretion of GnRH, or by reducing the synthesis and/or release of 
gonadotropins at the pituitary gland, or both, is not completely understood.  
 
In several early studies, in which this has been investigated by using GnRH challenge tests, 
results have been conflicting (Mishell et al., 1977; Perez-Lopez et al., 1975; Rubinstein et al., 
1978; Römmler et al., 1985; Vanderberg et al., 1974). Neither has the situation been 
elucidated in a more recent study, where pulsatile secretion of LH was investigated during 
the use of OCs (Hemrika et al., 1993). However, it was shown that the LH pulse pattern is 
strongly modified by feedback effects of the progestogen component of OCs. 
 
Although both the estrogen and progestogen components participate in pituitary-ovarian 
suppression, the overall effect probably being synergistic (Mishell et al., 1977, Römmler et 
al., 1985), it is generally accepted that ovulation prevention, through inhibition of the LH 
surge, is mainly generated by way of the progestogen component. The effect seems to be 
determined by the type and dose of progestogen (Dericks-Tan et al., 1976), as well as the 
duration of administration (Lähteenmäki, 1978; Römmler et al., 1985).  
 
Similarly to endogenous estrogen, EE2 may participate in inhibition of pituitary gonadotropin 
function only within a certain dose range. Even alone, at daily doses of 80 to 100 µg, EE2 is 
capable of impairing pituitary reactivity to GnRH release from the hypothalamus (Dericks-Tan 
et al., 1976; Römmler et al., 1985). Whether or not EE2 can act at much lower doses is 
unclear, with conflicting results (Römmler et al., 1985; Vanderberg et al., 1974). Oral 
contraceptives may also directly affect the ovaries, by depressing ovarian responsiveness to 
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gonadotropins (Mishell et al., 1971) or by inhibition of ovarian steroid biosynthesis (Aden et 
al., 1998; Kuhl, 1996).  
 
In addition to ovulation inhibition, OCs prevent normal proliferation of the endometrium 
(Chowdhury et al., 1980) and, more importantly, they change the cervical mucus, making it 
less penetrable to semen (Chowdhury et al., 1980; Hamilton and Hoogland, 1989; Killick et 
al., 1990; Morris et al., 1979; Spona et al., 1993). The former is affected by both the 
estrogenic and progestogenic components of the pill, whereas the latter results from the 
progestogenic effect on the mucus.  
 
 
2 CHARACTERISTICS OF OC STEROIDS  
 
Ethinylestradiol
  
is still the most widely used estrogen component of modern OC preparations 
in the world. Of the progestogens, norethisterone, levonorgestrel, gestodene, desogestrel, 
norgestimate and dienogest are 19-nortestosterone derivatives. Apart from dienogest, which 
was introduced latest, in 1991, these are still the most widely used progestogen components 
in OCs. Among them, levonorgestrel, gestodene, desogestrel and norgestimate belong to the 
subgroup of 13-ethyl-gonanes, as they contain a 13β-ethyl group. These derivatives are also 
called levonorgestrel-family progestogens (Edgren and Stanczyk, 1999) as well as 'gonanes', 
gonane being the basic structure of nearly all steroid hormones, including natural estrogens, 
progesterone, androgens and the corticosteroids (Kuhl, 1996).  
 
Norethisterone and dienogest belong to the norethisterone family of progestogens, ‘estranes’, 
which can also be characterized as 13-methyl-gonanes. Norethisterone acetate, ethynodiol 
diacetate and lynestrenol, which are still used in some OC formulations, are rapidly and 
completely converted to norethisterone (Kishimoto et al., 1972; Shrimanker et al., 1980). 
 
Whereas 19-nortestosterone derivatives in general retain varying degrees of androgenic 
activity, of the gonanes, gestodene, 3-keto-desogestrel and norgestimate have minimal 
androgenicity (Coenen et al., 1995; Janaud et al., 1992; Philips et al., 1990). Whilst gonanes 
have an ethinyl group at position 17α, dienogest has a 17α-cyanomethyl group, resulting in 
antiandrogenic properties (Kuhl, 1996). The 19-norprogesterone derivative nomegestrol 
(Kuhl, 1996) and the 17α-hydroxyprogesterone derivatives cyproterone and its acetate also 
  
14 
 
 
have antiandrogenic effects (Frey, 1975), the latter being used favorably in the treatment of 
hyperandrogenic symptoms (Erkkola et al., 1990). Drospirenone, a derivative of 17α-
spirolactone, has a unique pharmacological profile, notably antimineralocorticoid properties, 
which make it resemble endogenous progesterone (Oelkers, 2000). The 'evolution' of the 
current progestogens used in OCs is shown in Figure 1. 
 
 
 
 
     Figure 1 Current oral contraceptive progestogens 
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3 FACTORS AFFECTING THE RELIABILITY OF OCS 
 
3.1 Composition of the pill 
 
With reduction of steroid doses in OCs, the potency of the progestogen component becomes 
increasingly important for contraceptive reliability. In only a few clinical studies has the 
relative importance of the amount of EE2 versus progestogen, with respect to their potency in 
inhibiting ovulation, been elaborated, and the results have been conflicting. In a relatively 
recent study of three different OC regimens (20 µg EE2 /75 µg gestodene, 20 µg EE2 /150 µg 
desogestrel, and 30 µg EE2/150 µg desogestrel) it was concluded that EE2 content rather 
than the progestogenic component determined the extent of residual ovarian activity at the 
beginning of the pill-free period (van Heusden and Frauser, 1999). In another study, greater 
follicular activity was observed in women using a combination of 150 µg of desogestrel and 
20 µg of EE2, compared with women on a preparation of 150 µg desogestrel and 30 µg of 
EE2 (Mall-Haefeli, 1991). This also suggests a role of EE2 in the pituitary-ovarian 
suppression. However, in a large randomized double-blind comparison of two OCs 
containing 75 µg of gestodene combined with either 20 µg (n=428) or 30 µg (n=211) of EE2, 
two of three pregnancies occurred in the latter group, indicating comparable reliability with 
either preparation (Endrikat et al., 1997). Similarly, in almost 5000 cycles with two 
preparations, one containing 20 µg EE2 and 150 µg desogestrel and the other containing 30 
µg EE2 and 150 µg desogestrel, 0 and 2 pregnancies occurred, respectively (Åkerlund, 
1997). 
 
On the other hand, when the EE2 dose was fixed at 50 µg per day, divergent responses of 
LH and FSH during GnRH stimulation have been observed, depending on the type and dose 
of the progestogenic component (Römmler et al., 1985). Only a few large comparative 
studies evaluating the efficacy of different OCs have been carried out with preparations 
having 20 µg EE2. No significant difference was detected between preparations containing 20 
µg EE2/75 µg gestodene, and 20 µg EE2/150 µg desogestrel (Endrikat et al., 1995). Neither 
was there any difference in pregnancy rate between two OC regimens, both involving 20 µg 
EE2 and 100 µg levonorgestrel for 21 days, followed by either 7 hormone-free days or only 2 
hormone-free days and then 5 days of 10 µg of EE2 (Rosenberg et al., 1999). When a 
regimen of 20 µg EE2/100 µg levonorgestrel was compared with an OC regimen with 20 µg 
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EE2/500 µg norethisterone, the Pearl indices were 0.9 and 1.9, respectively (Endrikat et al., 
2001).  
 
In more closely monitored studies assessing ovarian activity during regular use of OCs 
containing either 20 µg EE2/150 µg desogestrel or 20 µg EE2/75 µg gestodene, no ovulation 
was detected (Crosignani et al., 1996; Fitzgerald et al., 1994; van Heusden and Frauser, 
1999). In addition, similar levels of residual ovarian activity were demonstrated with both 
preparations. However, ovarian activity appeared to be more suppressed with an OC that 
contained 20 µg EE2 and 150 µg of desogestrel, for 21 days, if followed by only 2 pill-free 
days and 5 days of 10 µg EE2, in comparison with one followed by 7 pill-free days (Killick et 
al., 1998). More pronounced ovarian suppression was also observed with a 20 µg EE2/75 µg 
gestodene preparation, if taken for 23 days followed by 5 pill-free days, compared with the 
traditional 21/7 regimen (Spona et al., 1996a). With a combination of 20 µg EE2 and 100 µg 
levonorgestrel, one ovulation was detected in a study on 26 women (Coney and DelConte, 
1999).  In another study, with the same combination, 24 women showed no escape 
ovulation, although a follicle-like structure larger than 13 mm in diameter was detected in half 
of the women (Spona et al., 1996b). With an ultra-low dose regimen of only 15 µg of EE2 and 
60 µg of gestodene one ovulation was detected among 75 regular cycles of 21-day pill-taking 
(Sullivan et al., 1999). 
 
Triphasic preparations contain lower amounts of steroids at the beginning of the pill pack, 
right after the pill-free interval, which itself confers follicular maturation. It has therefore been 
suggested that triphasic OCs would result in less complete pituitary-ovarian suppression, and 
hence an increased risk of functional ovarian cysts, compared with the use of monophasic 
preparations. However, this view is largely derived from case-reports and uncontrolled 
studies (Caillouette and Koehler, 1987; Kovacs et al., 1989; Römmler et al., 1985; Smith et 
al., 1986; Van der Vange et al., 1985), whereas results from more strictly controlled studies 
do not support it (Crosignani et al., 1996; Gaspard et al., 1984; Grimes et al., 1994; Holt et 
al., 1992; Killick et al., 1990; Lete and Morales 1997; Spona et al., 1993; Young et al., 1992). 
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3.2 Absorption and bioavailability of OC steroids  
 
All factors which decrease either direct absorption of steroids, or their re-entry from the 
intestine to the circulation (enterohepatic recirculation), may adversely influence pill efficacy. 
Vomiting soon after pill intake may obviously prevent initial absorption of contraceptive 
steroids.  
 
After oral administration, steroids in OCs are absorbed as free or conjugated (mainly with 
sulfate) within the small intestinal wall. It is well established that orally given EE2 is 
substantially metabolized by the intestine, reducing its bioavailability by more than 50% (Back 
et al., 1979; Back et al., 1982a). Norethisterone also undergoes considerable first-pass 
metabolism in vivo during passage through the intestinal wall, resulting in overall 
bioavailability of 64% (Back et al., 1978b).  
 
Desogestrel, which is a prodrug, is rapidly transformed to its active metabolite 3-keto-
desogestrel (Madden et al., 1989; Viinikka, 1979). Norgestimate may also be a prodrug, at 
least partly: it is metabolized initially to levonorgestrel-3-oxime, but it probably exerts its 
pharmacodynamic effect mainly through its metabolite levonorgestrel (Kuhl, 1996; Kuhnz et 
al., 1993b; Madden and Back, 1991). Norgestimate and desogestrel are metabolized by the 
gut wall in vitro (Back et al., 1990; Madden and Back, 1989), but as both progestogens are 
readily and almost completely metabolized to their active metabolites, there is no accurate 
data on in vivo bioavailability (Hasenack et al., 1986; Kuhnz and Gieschen, 1998). However, 
the estimated bioavailability of norgestimate is around 60% (McGuire et al., 1990) and mean 
(±SD) bioavailability figures of 76±22% (Back et al., 1987) and 62±7% (Orme et al., 1991) 
have been reported for desogestrel.  
With gestodene (Kuhl et al., 1988b; Täuber et al., 1990) and levonorgestrel (Back et al., 
1981b; Hümpel et al., 1978), which are active drugs themselves, nearly 100% bioavailability 
has been described. Whether the compound is a prodrug or active itself is probably not of 
great importance with regard to its pharmacological profile (Hammerstein, 1990).  
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3.3 Enterohepatic recirculation of OC steroids 
 
Absorbed free steroid may be conjugated by the liver with glucuronic acid or hydroxylated by 
oxidative liver enzymes. Variable amounts of conjugated steroids, mainly sulfates, are 
excreted in the bile, released into the colon, hydrolyzed by intestinal microflora, and then 
reabsorbed as free steroid back to the portal venous system and to the liver (Orme et al., 
1983). This process is called enterohepatic recirculation and is illustrated in 
Figure 2.  
 
Both intestinal microflora, and mucous cell metabolism are thought to be responsible for the 
metabolism and reabsorption of steroids from the intestine (Adlercreutz et al., 1979). In 
severe diarrhea, both accelerated motility of the bowel and the degree of inflammation in the 
gut wall influence the overall effect of the pill. Since the gut microflora is largely responsible 
for hydrolysis of steroid conjugates, antibiotic treatment, most notably ampicillin and 
tetracycline, may lead to an increased fecal loss of steroid conjugates and consequently a 
decrease in the concentrations of circulating free steroids.  
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Figure 2  Schematic representation of the enterohepatic circulation of orally administered OC 
steroids. (Adopted from: Orme and Back, 1986, with permission) 
 
Enterohepatic circulation has been clearly demonstrated for EE2 (Back et al., 1979; Back et 
al., 1980b; Back et al., 1981b). It has also been speculated that enterohepatic circulation may 
be relevant only for EE2, because it is directly conjugated at position 3, unlike progestogens 
(Orme and Back, 1990). The ethinyl group at the 17-position, present both in EE2 and in 
gonane progestogens, has been thought to hinder conjugation and, thus, the enterohepatic 
circulation of progestogens (Back et al., 1981a). However, in man, glucuronidation at the 17-
position has been shown to occur extensively in both EE2 (Sahlberg et al., 1981) and 
norethisterone (Braselton et al., 1977). In the rat it has been demonstrated that antibiotic 
treatment reduces enterohepatic cycling of norethisterone, even though there was no 
evidence of direct conjugation (Back et al., 1978a; Back et al., 1980c).  
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Clinical evidence as regards the enterohepatic circulation of progestogens is negligible and 
conflicting. Double peaks of serum EE2 and norethisterone have been documented between 
4–7 hours after oral administration of the steroids, suggesting their enterohepatic recirculation 
(Zacur et al., 1992). The bioavailability of levonorgestrel has been studied in women with 
ulcerative colitis, but the results have been inconclusive (Nilsson et al., 1985). Women with 
mild ulcerative colitis, who were treated by proctocolectomy and continent ileostomy, showed 
lower serum levonorgestrel concentrations than did healthy women serving as controls 
(p<0.05). In another study, the mean bioavailablity of levonorgestrel was not statistically 
significantly decreased in women who had undergone ileostomy following lower bowel 
surgery (Grimmer et al., 1986).  
 
 
3.4 Plasma concentrations and distribution of OC steroids 
 
As regards all contraceptive steroids, there are many-fold intersubject and interpopulation 
differences in serum levels (Back et al., 1979; Kuhl et al., 1988a; Kuhl et al., 1988b; Shi et al., 
1987). A number of environmental factors may affect the serum concentrations of OC 
steroids, but less than 30% of the variation has been explained by factors such as lifetime 
use of OCs, time since ingestion of the last pill, day of the menstrual cycle, race, age, weight, 
height, blood pressure, alcohol and cigarette consumption and diurnal variation (Stadel et al., 
1980). In an individual woman, however, serum levels remain relatively constant from cycle 
to cycle (Kuhl et al., 1988a; Kuhl et al., 1988b). 
 
In general, the maximum serum concentration (Cmax) values of contraceptive steroids are 
reached within 1–2 hours of oral intake (Orme et al., 1983). The time interval to peak 
concentration (tmax) of active metabolites after oral ingestion of a prodrug occurs about one 
hour later than that of the active drug itself (Hammerstein, 1990; Pasqualini et al., 1977; 
Sarkar et al., 1983). This, however, does not affect the efficacy of contraceptive steroids as 
long as absorption of the drug is complete. 
 
All contraceptive steroids are bound to carrier proteins in the plasma and only the unbound 
fraction, less than 5% of the total, is considered biologically active (Hammond et al., 1984; 
Orme et al., 1983). Around 95–98% of plasma EE2 is bound, virtually all to albumin, whereas 
progestogens are bound to both albumin and sex hormone-binding globulin (SHBG). 
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Progestogens differ in their potency to inhibit ovulation, partly due to their different binding 
affinities to plasma proteins (Kuhl, 1996). Gestodene and levonorgestrel are 98% bound, 
gestodene more notably to SHBG (70–80% after multiple doses), and levonorgestrel slightly 
more to albumin (Fotherby, 1990; Hammond et al., 1984; Kuhnz et al., 1992; Kuhnz et al., 
1993a). More than 60% of 3-ketodesogestrel and norethisterone are bound to albumin and 
30–35% to SHBG (Fotherby, 1990; Hammond et al., 1994; Orme et al., 1983), thus showing 
lower affinity to carrier proteins, because binding to albumin appears to be much weaker than 
to SHBG (Orme et al., 1983; Fotherby, 1990). 
 
Of all progestogens, gestodene has been considered to be biologically the most potent, 
probably because it binds largely to SHBG (Back et al., 1993; Hammond et al., 1994; Kuhl, 
1996). A lower dose of gestodene results in similar or higher serum concentrations when 
compared with other progestogens (Back et al., 1993; Hammond et al., 1994). However, 
serum concentration alone does not always correlate with biological potency, if expressed as 
potency to prevent ovulation (Fotherby, 1990; Gillmer, 1987). For example, dienogest, with a 
low affinity to progesterone receptor and relatively high serum concentrations, has a strong 
effect on the endometrium and cervical mucus, but relatively low ovulation-inhibiting potency 
(Kuhl, 1996). Gestodene has been demonstrated to be the most potent compound in terms of 
the lowest dose required for ovulation inhibition (40 µg vs. 60 µg levonorgestrel and 
desogestrel, 400 µg norethisterone) and it is used at the lowest doses in OCs (60–75 µg, vs. 
100–150 µg levonorgestrel and desogestrel, 1000 µg norethisterone) (Fotherby, 1990; Kuhl, 
1996; Spona et al., 1993). 
 
Ethinylestradiol itself induces hepatic synthesis of SHBG, thus leading to increased serum 
SHBG-bound progestogen and, consequently, a decreased free fraction. Levonorgestrel, as 
an antiestrogenic progestogen, can oppose this effect (Victor and Johansson, 1977), 
whereas others such as gestodene and desogestrel lack this property (Hammond et al., 
1984).  
 
The higher the binding affinity to SHBG the stronger the distribution towards the SHBG-
bound fraction. Hence, gestodene is more affected by EE2-induced SHBG synthesis than 
progestogens with less affinity to SHBG. Although only a non-protein-bound progestogen is 
considered to be biologically active, there is no evidence that the relative decrease of free 
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progestogen results in impairment of contraceptive efficacy (Fotherby, 1990; Hammond et al., 
1994). Regarding gestodene, this may be explained by the relatively very high serum 
concentrations of both the free and protein-bound components achieved after a considerably 
smaller dose compared with other progestogens. Furthermore, strong binding to SHBG may 
restrict the distribution of gestodene to other body fluids and tissues (Orme et al., 1991).  
 
 
3.5 Accelerated metabolism and excretion 
 
Gonanes are considered to be much more potent than estranes, as the 13-ethyl group of 
gonanes protects them against rapid liver metabolism through inhibition of cytochromal P450 
(CYP) enzymes in the liver; more specifically 5α-reductase and CYPIIIA4 isoenzymes (Kuhl, 
1996). This inhibition of CYP enzymes may contribute to impairment of follicular development 
and prevention of ovulation.  
 
While most of the OC steroid conjugates excreted in bile are sulfates, in urine they are 
excreted chiefly as glucuronides and to a lesser extent as sulfates (Orme et al., 1983). As 
explained in section 3.3, impairment of enterohepatic recirculation of OC steroids may lead to 
excessive fecal elimination of steroid conjugates, and thus to reduction of contraceptive 
efficacy. 
 
 
3.6 Noncompliance in pill taking 
 
In a interview study among 769 ‘reliable pill takers’, noncompliance in pill taking was 
excluded on the basis of the results of a questionnaire which was completed at the time a 
woman was attending for termination of pregnancy (Sparrow, 1998). One third of the women 
who experienced accidental pregnancy during use of an OC or progestogen-only pills did not 
report any known predisposing factor such as gastroenteritis or drug interaction. These cases 
were thus treated as method failures. In two thirds of the women who reported a factor 
interfering with their OC, pregnancy was most often associated with vomiting and/or diarrhea 
(39%) and with concurrent antibiotic treatment (21%). Over a quarter (28%) of the women 
had also experienced previous pill failure.  
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In another study, 800 OC failures were identified from hospital records among 8192 women 
who had undergone pregnancy termination. Eventually, after validation of the data, one third 
of these 800 women appeared not to have been using an OC at the time of conception 
(Skjeldestad, 2000). 
 
Studies in different populations demonstrate great variation (3–60%) in the proportions of oral 
contraceptive users who self-report missed pills (Potter, 1996). However, as in the above-
mentioned studies, these studies are based on interviews with women and/or the use of daily 
diaries in which women have been asked to record their tablet taking. Definitions of ‘late’ or 
‘missed’ pills are also different from study to study (Potter, 1996). In general, up to 20% of 
women report that they have omitted two or more pills per cycle and almost half of the 
women on OCs miss one or more pills in each cycle (Rosenberg et al., 1995; Rosenberg et 
al., 1998).  
 
Only recently, by way of use of electronic pill dispensers, augmented with a precoded 
microchip, has it been shown that the real incidence of missed pills is much higher than 
reported by women, and the discrepancy also increases over time (Potter et al., 1996). 
During the first two treatment cycles the electronic data showed that over 30% of women 
forgot ≥3 pills, whereas only 10% of women reported that they had forgotten that number. 
During the third cycle it was recorded electronically that more than 50% of users missed ≥3 
pills, compared with self-reports of only 14% (Potter et al., 1996).  
 
As shown in Table 1, in studies in which noncompliance has been simulated by timed 
omission of 1 to 4 pills, no ovulation has been demonstrated almost exclusively (Hamilton 
and Hoogland, 1989; Hedon et al., 1992; Letterie and Chow, 1992; Morris et al., 1979; Nuttal 
et al., 1982; Wang et al., 1982). In one study, however, almost one third of the women 
ovulated after deliberate omission of two consecutive pills between cycle days 5–17 
(Chowdhury et al., 1980). Ovulation was determined by elevation of serum progesterone of 
>4 ng/ml. It was suggested that the high failure rate could be explained either by the OC 
regimen used in the study or by noncompliance. In contrast, in another study, no luteinization 
was seen during 7 pill-free days which were preceded by only 7 days of pill-taking (Smith et 
al., 1986).  
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Table 1 The risk of ovulation after pill omission (excluding extended pill-free periods) 
Study Number of missed 
pills and time of cycle 
No. of ovulations/ 
No. of subjects 
OC cycle  Regimen(s) 
Chowdhury et al., 1980 2 consecutive pills 
anytime between pill 
days 5-17 
10/35 
5/19 
1st 
4th 
N=54:35 µg EE2 + 1.0 mg NET Ac 
Hamilton and Hoogland, 
1989 
1 (pill no. 2) 0/9 2nd   N=9: 35 µg EE2 + 0.5   mg NET  (7 days),  
         35 µg EE2 + 0.75 mg NET  (7 days),  
         35 µg EE2 + 1.0   mg NET  (7 days) 
Hedon et al., 1992 1-4 pills, started on pill 
day: 
6  
12  
18 
 
 
0/7 
0/7 
0/10*) 
2nd   N=24:35 µg EE2 + 250 µg NGM  
Letterie and Chow, 1992 4 (pills no. 3-6) 
4 (pills no. 6-9) 
0/5 
0/5 
Not 
stated 
N=10:35 µg EE2 + 0.5   mg NET (7 days),  
          35 µg EE2 + 0.75 mg NET (7 days),  
          35 µg EE2 + 1.0   mg NET (7 days) 
Morris et al., 1979 1 (pill no.4) 
1 (pill no. 19) 
0/7 
0/3 
3rd or 
later 
N=10:30 µg EE2 + 150  µg  LNG 
Nuttal et al., 1982 1 (pill no.10) 
2 (pills no. 9-10) 
0/6 
0/6 
2nd 
3rd 
N=6:  20 µg EE2 + 250  µg  LNG 
Wang et al., 1982 2 (pills no. 3-4) 
2 (pills no. 6-7) 
2 (pills no. 9-10) 
0/8 
0/8 
0/8 
4th or 
later 
N=24:30 µg EE2 + 150  µg  LNG 
 
*
)
 3 subjects with 4 missed pills starting on pill day 18 are included in Table 3, as the situation is identical to an extended pill-free period. 
LNG = levonorgestrel, NET = norethisterone, NET Ac = norethisterone acetate, NGM = norgestimate 
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3.7 The pill-free interval and residual ovarian activity 
 
In general, a follicle exceeding 10 mm in diameter is considered to be a 
prerequisite for further development of the follicle, whereas a smaller follicle 
does not seem to have any activity. A diameter of 13 mm has been thought to 
be critical in terms of ovulation (Hoogland and Skouby, 1993). Grading of 
ovarian activity, as determined by the size of a follicle-like structure and serum 
estradiol and progesterone concentrations, is shown in Table 2 (Hoogland and 
Skouby, 1993). In the present study all follicle-like structures are consistently 
called follicles, even though their activity is not possible to determine in 
ultrasonographic examination and, therefore, a follicle-like structure would be a 
more accurate term. 
 
Table 2  Grading of follicular activity 
Grade of ovarian 
activity 
Follicle-like 
structure (mm) 
S-Estradiol  
(pmol/L) 
S-Progesterone 
(nmol/L) 
0 No activity ≤ 10   
1 Potential activity > 10   
2 Non-active FLS > 13 ≤ 100  
3 Active FLS > 13 > 100 ≤ 5 
4 LUF > 13, persisting > 100 > 5 
5 Ovulation > 13, ruptured > 100 > 5 
FLS = Follicle-like structure 
LUF = Luteinized unruptured follicle 
 
 
Ovarian activity, especially during the pill-free period, has been clearly 
demonstrated even with pills containing 30 µg of EE2 or more, by way of raised 
serum gonadotropin and estradiol levels (Cohen and Katz, 1979; Killick et al., 
1987; Lähteenmäki and Luukkainen, 1978; Smith et al., 1986) and by detecting 
follicular development by ultrasonography (Hamilton and Hoogland, 1989; Killick 
et al., 1987; Tayob et al., 1990; Van der Vange et al., 1985). Whilst follicular 
activity grading 2 or higher (see Table 2) counts in 23 - 37% of cycles of women 
using OCs containing 30 µg of EE2 or more (Hamilton and Hoogland, 1989; 
Tayob et al., 1990), the grade 2 - 5 has been detected in 9 - 60% of the cycles 
with low-dose preparations of only 20 µg EE2 (Crosignani et al., 1996; Fitzgerald 
et al., 1994; Spona et al., 1996a; van Heusden and Frauser, 1999).  
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These findings have led to the idea that missing the first pills of the pack, 
thereby extending the pill-free period, would be critical as regards escape 
ovulation (Fraser and Jansen 1983; Killick et al., 1990; Landgren and 
Csemiczky, 1991; Landgren and Diczfalusy, 1984; Wang et al., 1982). However, 
in studies in which noncompliance has been simulated by extending the pill-free 
period to 8–11 days, the results have been inconclusive. Whilst in one study 
only the first pill was omitted during the second pill cycle and one of nine women 
ovulated (Hamilton and Hoogland, 1989), no ovulation was detected after an 11-
day pill-free period (Hedon et al., 1992; Killick et al., 1990; Letterie and Chow, 
1992). Studies in which pituitary-ovarian inhibition has been challenged by 
extending the pill-free period are presented in Table 3. In these studies both 
mono- and triphasic preparations have been used, with a variety of 
progestogens and with a minimum daily EE2 dose of 30 µg.   
 
In one study, the duration of the pill-free period was extended until a 
predetermined size of dominant follicle was reached, as detected by 
ultrasonography (Killick, 1989). At the stage when the leading follicle had 
reached a diameter of 12 mm (in 7–16 days in individual women), the women 
were asked to resume pill-taking. Eight of ten women continued to develop 
preovulatory follicles of 18 mm in diameter, and all eight women ovulated within 
48 hours after administration of human chorionic gonadotropin (HCG). It was 
concluded that ovulation was induced by HCG and that pill omissions may lead 
to ovulation if they take place at the stage when follicular development is optimal 
(Killick, 1989). In another study, a regimen of 50 µg EE2 and 1 mg 
norethisterone for 5 days, followed by 0.7 mg of norethisterone alone for 
subsequent 9 days, and then by 14 days on placebo was started either 6 days 
(group 1) or 8 days (group 2) after the onset of menses (Letterie, 1998). It was 
claimed that the studied regimen gives effective prevention against pregnancy. 
During the second cycle, i.e. after resuming the pills, one of five women ovulated 
in group 1 and all 5 women ovulated in group 2. No data has been published on 
the effect of additional pill omissions in circumstances in which the extended pill-
free period has resulted in a preovulatory follicle. 
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Table 3 Studies evaluating the risk of escape ovulation resulting from an extended pill-free period 
Study Number of missed first/ 
last  pills of the packet 
No. of ovulations/ 
No. of subjects 
OC cycle  Regimen(s) 
Dericks-Tan et al., 1980 2  1/5 *)1st N=9: 37.5 µg EE2 + 0.75 mg LYN 
 
Hamilton and Hoogland, 
1989 
1  1/9 2nd   N=9:  35 µg EE2 + 0.5    mg NET  (7 days),  
          35 µg EE2 + 0.75  mg NET  (7 days),  
          35 µg EE2 + 1.0    mg NET  (7 days) 
Hedon et al., 1992 1  
2  
3  
4  
0/4  
0/4 
0/4 
0/6 
2nd   N=18:35 µg EE2 + 250   µg NGM  
Killick et al., 1990 2  
4  
0/14 
0/14 
2nd and 3rd,  
intra-
individual 
cross-over 
 
N=10: 35 µg EE2  + 150  µg LNG  
N=9:   35 µg EE2  + 150  µg LNG  (6 days),  
           40 µg EE2  +  75   µg LNG  (5 days),  
           30 µg EE2  + 125  µg LNG  (10 days)    
N=9:   30 µg EE2  +  75   µg GEST  
Landgren and Diczfalusy 
1984 
2 0/10 4th or later,  
3 consecutive 
cycles 
N=10: 30 µg EE2 + 150   µg LNG 
Landgren and Csemiczky, 
1991 
3  1/10 
1/10 
4th or later N=10: 30 µg EE2  + 150  µg  DSG  
N=10: 35 µg EE2  + 150  µg  LNG (6 days),  
           40 µg EE2  +  75   µg  LNG (5 days),  
           30 µg EE2  + 125  µg  LNG (10 days)   
Letterie and Chow, 1992 4  0/5 Not known N=5:   35 µg EE2  +  0.5  mg NET  (7 days),  
           35 µg EE2 + 0.75  mg NET (7 days),  
           35 µg EE2 +  1.0   mg NET (7 days) 
Wang et al., 1982 2 0/8 4th or later N=8:   30 µg EE2  + 150   µg  LNG 
*
)Pills started on day 10 of the initial cycle, DSG = desogestrel, GEST = gestodene, LNG = levonorgestrel, LYN = lynestrenol, NET = norethisterone, 
NGM = norgestimate 
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3.8 Drug interactions 
 
Concomitant medication can theoretically reduce the efficacy of OCs by a variety of 
mechanisms. It may interfere with the initial absorption of OC steroids or with their 
reabsorption, i.e. enterohepatic recirculation, induction of CYP enzyme activity in the liver, or 
serum protein binding capacity of OC steroids. Finally, urinary excretion of OC steroids may 
be increased by concurrent medication (DeSano and Hurley, 1982).  
 
The first report on the possible loss of contraceptive efficacy described increased 
intermenstrual bleeding in OC users who had concurrently received rifampicin and other 
antituberculous drugs (Reimers and Jezek, 1971). Since then numerous case reports have 
been documented and experiments performed to investigate the underlying mechanisms of 
drug interactions. 
 
Rifampicin (Joshi et al., 1980a), rifabutin (Barditch-Crovo et al., 1999) and certain 
anticonvulsants, such as barbiturates and their derivatives, phenytoin, carbamazepine and 
their derivatives (Back et al., 1980a; Crawford et al., 1990) are capable of inducing CYPIIIA4 
isoenzymes in the liver, which participate in the 2-hydroxylation of EE2. The carbamazepine 
derivative oxcarbazepine, as well as felbamate and topiramate, may also induce hepatic CYP 
enzymes, although to a lesser extent (Jensen et al., 1992; Larkin et al., 1991; Wilbur and 
Ensom, 2000). The second-generation antiepileptic agents gabapentin, lamotrigine, tiagabine 
and vigabatrin, may be given to OC users without significant pharmacokinetic interactions 
(Bartoli et al., 1997; Wilbur and Ensom, 2000). Pregnancies during use of the antituberculous 
drug isoniazid are likely to be a result of concurrent use of rifampicin (Joshi et al., 1980a).  
 
The same agents that induce CYP enzymes in the liver are capable of increasing SHBG 
binding capacity for progestogens, thereby resulting in a decrease in their free plasma 
concentrations (Back et al., 1980d; Orme and Back 1980; Victor et al., 1977). Whether this 
leads to a reduction in contraceptive efficacy has not yet been proven.  
 
Broad-spectrum antibiotics, such as penicillin, tetracycline and their derivatives, have been 
thought to interfere with enterohepatic recirculation of OC steroids. There are several 
anecdotal reports on OC users who have experienced breakthrough bleeding or pregnancy 
when given broad-spectrum antibiotics (Back et al., 1988; Bacon and Shenfield, 1980; 
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Bainton, 1986; DeSano and Hurley, 1982). Although ampicillin treatment has been shown to 
interfere dramatically with the gut bacteria responsible for hydrolysis of steroid conjugates, 
controlled studies have almost systematically failed to show any association between broad-
spectrum antibiotics and pill failure (Back et al., 1982b; Friedman et al., 1980; Joshi et al., 
1980b). Similarly, no signs of reduced contraceptive efficacy have been documented during 
concurrent use of tetracycline derivatives (Murphy et al., 1991; Neely et al., 1991; Orme and 
Back 1986), erythromycin (Orme and Back 1986), cotrimoxazole (Grimmer et al., 1983), 
temafloxacin (Back et al., 1991), fluoroquinolone (Csemiczky et al., 1996), roxithromycin 
(Meyer et al., 1990), or metronidazole (Joshi et al., 1980b). In a retrospective cohort study 
involving 311 woman-years of use of OCs and concurrent antibiotics, and 1245 woman-years 
of OC exposure alone, no difference was detected in pregnancy rates (Helms et al., 1997). 
A few anecdotal cases of unintended pregnancies have been reported in women using H1 
antagonists (DeSano and Hurley, 1982), laxatives (Köhler et al., 1976), griseofulvin (Van 
Dijke and Weber, 1984), and azol antifungals (Pillians and Sparrow, 1993). However, with the 
exception of griseofulvin, these agents have been considered to confer no risk during the use 
of OCs (CSAC, 1989; Hilbert et al., 2001; Lunell et al., 1991; Sinofsky and Pasquale, 1998). 
 
Since charcoal is not absorbed from the gastrointestinal tract, it prevents the absorption of 
steroids from both the stomach and intestine. This fact has been utilized in the treatment of 
patients who have ingested poisonous substances. The effect of activated charcoal on the 
bioavailability of steroids has been previously studied in connection with the antiprogestin 
mifepristone (RU 486) (Heikinheimo et al., 1989). Activated charcoal was ingested 
repeatedly, starting 6 hours after oral administration of 200 mg of mifepristone. A clear 
reduction in serum mifepristone levels was seen on day 1, in comparison with the controls. 
This suggests impaired enterohepatic recirculation of mifepristone. Significantly reduced 
plasma estriol concentrations have been measured in menopausal women 2 hours after the 
intake of 20 g of activated charcoal, when administered three hours after the oral estriol 
(Heimer and Englund, 1986). In an in vitro study, activated charcoal has been shown to be a 
very powerful adsorbent of steroids (Fadel et al., 1979). In the presence of different 
adsorbents, i.e. antacids, peptic ulcer drugs, and activated charcoal, the last named reduced 
the dissolution of norethisterone acetate most efficiently. Antacid did not affect the 
bioavailability of contraceptive steroids in women using OCs (Joshi et al., 1986).  
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Drugs that have been reported to reduce the contraceptive efficacy of OCs, suspected 
mechanisms of interaction, level of documentation and the clinical significance of the 
interaction are presented in Table 4. 
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Table 4  Drugs claimed to reduce the efficacy of OCs 
Drug Suspected mechanism  Documentation Clinically 
significant 
References 
Anticonvulsants 
Barbiturates, 
Carbamazepine, 
Phenytoin 
Oxcarbazepine,  
Felbamate, 
Topiramate 
 
CYP enzyme induction  
 
 
CYP enzyme induction 
 
 
Established  
 
 
Possible  
 
 
Yes 
 
 
Yes 
 
 
 
Back et al., 1980a; Crawford et al., 1990 
 
 
Jensen et al., 1992; Larkin et al., 1991;  
Wilbur and Ensom, 2000 
Antituberculous drugs 
Rifampicin, 
Rifabutin 
Isoniazid 
 
CYP enzyme induction 
 
No known mechanism 
 
Established  
 
Doubtful  
 
Yes 
 
No 
 
Joshi et al., 1980a; Reimers and Jezek, 1971;  
Barditch-Crovo et al., 1999 
Joshi et al., 1980a 
Antimycotics 
Griseofulvin 
Azole derivatives 
 
CYP enzyme induction 
No known mechanism 
 
Possible  
Doubtful  
 
Yes 
No 
 
Van Dijke and Weber, 1984 
Lunell et al., 1991; Pillians and Sparrow, 1993 
Broad-spectrum antibiotics  
Penicillin and derivatives  
 
 
Tetracycline and derivatives  
  
 
Decreased reabsorption  
due to interruption of EHC 
 
Decreased reabsorption  
due to interruption of EHC 
 
Possible  
 
 
Possible 
 
 
? 
 
 
? 
 
Back et al., 1982b; Back et al., 1988; Bacon and Shenfield, 1980; 
Bainton, 1986; DeSano and Hurley, 1982; Friedman et al., 1980; 
Joshi et al, 1980b 
Murphy et al., 1991; Neely et al., 1991;Orme and Back, 1986 
Other antibiotics 
Cotrimoxazole 
Erythromycin  
Temafloxacin  
Fluoroquinolone 
Roxithromycin 
Metronidazole 
 
Decreased reabsorption  
due to interruption of  
EHC?/ 
No known mechanism 
 
Doubtful  
 
 
No 
 
 
 
Grimmer et al., 1983  
Orme and Back 1986  
Back et al., 1991  
Csemiczky et al., 1996 
Meyer et al., 1990  
Joshi et al., 1980b 
Adsorbents 
Activated charcoal 
 
Antacids 
 
 
Decreased absorption and 
reabsorption 
Decreased absorption and 
reabsorption 
 
Possible  
 
Doubtful  
 
? 
 
No 
 
Fadel et al., 1979; Heikinheimo et al., 1989;  
Heimer and Englund, 1986 
Fadel et al., 1979; Joshi et al., 1986 
Laxatives  
only strong and fast-acting cathartics 
 
Decreased absorption and 
reabsorption 
 
Possible  
 
? 
 
Köhler et al., 1976 
Antihistamines 
H1 antagonists 
 
CYP enzyme induction? 
 
Doubtful  
 
No 
 
CSAC, 1989; DeSano and Hurley, 1982 
CYP = cytochromal P450, SHBG = sex hormone-binding globulin, EHC = enterohepatic circulation 
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3.9 Other factors predisposing to pill failure 
 
A higher frequency of spotting or breakthrough bleeding has been reported in smokers who 
use OCs, compared with non-smoking women on OCs (Rosenberg et al., 1996). It has been 
suggested that this may be connected to the increased clearance of EE2 described in 
smokers (Breckenridge et al., 1980; Kanarkowski et al., 1988). However, in a study with more 
than 300 women, smoking did not affect the overall rate of either EE2 or levonorgestrel 
metabolism (Crawford et al., 1981), and nicotine is known to induce CYPIA2 isoenzyme, 
whereas EE2 is metabolized via CYPIIIA4 isoenzyme (Pelkonen et al., 1998). 
 
According to some investigators, smoking seems to be strongly associated with inadvertent 
pregnancies during pill use (Kakouris and Kovacs, 1994; Sparrow, 1998). Kakouris and 
Kovacs (1994) compared two cohorts, one of OC users who experienced inadvertent 
pregnancy and one of non-pregnant OC users, over two different time periods, to evaluate 
predisposing factors associated with pill failure. In the pregnant group, smoking was much 
more common. There was no difference in the prevalence of any other known risk factor, 
such as vomiting, diarrhea or concurrent drug use, but there were five times more teenagers 
in the pregnant group. Hence, it was concluded that pill failure may have occurred more often 
among smokers not because of smoking per se but because of other factors predisposing 
women to compliance problems, such as young age.  
 
The same probably applies to alcohol consumption and pill failure. Alcohol drinking may 
confer an increased risk of forgetting pills, but there is no evidence of pharmacological 
interactions between ethanol and oral contraceptive steroids which may reduce their 
contraceptive efficacy (Sarkola, 2001; Winstanley and Orme, 1989). No alteration was 
detected in serum levonorgestrel concentrations in rats receiving oral levonorgestrel after six-
week exposure to alcohol (Gomaa et al., 1984). However, following intravenous 
administration, the elimination half-life of levonorgestrel was shorter and its metabolic 
clearance rate higher in the ethanol-treated rats than in the control group. 
 
Food may affect drug bioavailability in many ways, but no clinically significant interactions 
have been shown with OCs (Winstanley and Orme, 1989). The clearance of norethisterone 
has been found to be accelerated in Indian women of poor nutritional and socio-economic 
status, compared with women belonging to a high socio-economic group (Prasad et al., 
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1979). The termination half-life of norethisterone correlated positively with the body mass 
index of these women. It is unclear whether the shorter termination half-life  was due to low 
body mass index or altered metabolism resulting from malnutrition. 
 
It has been suggested that severe psychological stress and systemic illness, other than 
gastroenteritis (John and Jones, 1975; Hansen and Lundvall, 1997; Sparrow, 1998) or 
chronic bowel disease (Grimmer et al., 1986; Nilsson et al., 1985) may affect the utilization of 
pill steroids (Sparrow, 1998). However, it is not known how severe stress might affect pill 
efficacy. 
 
Ovarian suppression has been shown to be greater in women on OCs who are over 35 years 
of age (Fitzgerald et al., 1999). This is due to an age-dependent increase in serum FSH 
levels which reflects increased ovarian resistance to follicular development.  
 
When OCs that contained EE2 and norethisterone were administered at various times of the 
day, no association was detected between a number of pharmacokinetic parameters and the 
different times of administration (Kiriwat and Fotherby, 1983). If OCs are taken regularly, no 
difference is expected in their efficacy during the initial cycle or later pill cycles, even though 
steady serum concentrations of OC steroids are established only after 1–3 months of use 
(Kuhl et al., 1988b; Kuhnz et al., 1993a). 
 
Factors other than drug interactions that have been thought to relate to pill efficacy are 
summarized in Table 5. 
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Table 5 Factors reported to reduce the efficacy of OCs, other than drug  interactions 
Factor Suspected mechanism  Documentation Clinically 
significant 
References 
Noncompliance in pill 
taking 
Low serum steroid levels Established 
 
Yes See Tables 1 and 3 
Vomiting 
Diarrhea 
Decreased absorption  
Decreased absorption and 
reabsorption due to interruption  
of EHC 
Established 
Possible 
 
Yes 
? 
Adlercreutz et al., 1979;  
Hansen and Lundvall, 1997;  
John and Jones, 1975;  
Sparrow, 1998 
Chronic bowel disease Decreased reabsorption  
due to interruption of EHC 
Doubtful 
 
No Grimmer et al., 1986;  
Nilsson et al., 1985 
Systemic illness/stress No known mechanism Doubtful 
 
No Sparrow, 1998 
Smoking CYP enzyme induction   Doubtful 
 
No Breckenridge et al., 1980; 
Crawford et al., 1981; 
Kakouris and Kovacs, 1994;  
Kanarkowski et al., 1988;  
Rosenberg et al., 1996; Sparrow, 1998 
Acute or chronic  
use of alcohol 
CYP enzyme induction? Doubtful 
 
No Gomaa et al., 1984; Sarkola, 2001; 
Winstanley and Orme, 1989 
Diet Delayed or decreased absorption Doubtful 
 
No Winstanley and Orme, 1989 
Poor nutrition/ 
low BMI 
Altered metabolism,  
shorter elimination half-life? 
Doubtful 
 
No Prasad et al., 1979 
Ethnic factors Different liver metabolism Possible 
 
? Stadel et al., 1980 
Time since initiation of 
OCs 
Delayed steady-state serum 
steroid concentrations 
Doubtful 
 
No Kuhl et al., 1988b;  
Kuhnz et al., 1993a 
Time of administration Diurnal variation of metabolism Doubtful 
 
No Kiriwat and Fotherby, 1983 
EHC = enterohepatic circulation
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III AIMS OF THE STUDY 
 
The present study was aimed at elucidating the risk of escape ovulation during 
the use of OCs, to allow us to provide fuller information to women using OCs. 
More specifically they were: 
 
To investigate if there are differences between OC regimens in their potency to 
inhibit ovulation, when challenged by extending the pill-free period by a fixed 
number of days. 
 
To assess the ovulatory potential of follicles allowed to grow to a predetermined 
size, before restarting OC treatment.  
 
To test whether oral administration of activated charcoal could inhibit the 
enterohepatic recirculation of the oral contraceptive steroids gestodene and 
norethisterone, thus conferring a risk of escape ovulation during regular OC use. 
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IV MATERIALS AND METHODS 
 
1 DESIGN OF THE TRIALS, AND TRIAL SITES 
 
The present study was conducted at three centers: the Family Planning Clinic 
(later: the Sexual Health Clinic) of the Family Federation of Finland (Väestöliitto), 
Helsinki, Finland (studies I-IV); the Department of Obstetrics and Gynecology, 
University Hospital St. Radboud, Nijmegen, The Netherlands (study I); and the 
Department of Obstetrics and Gynecology, University Hospital of Gasthuisberg, 
Leuven, Belgium (study I). 
 
Of the total of 128 recruited subjects, 125 were enrolled and 115 women 
completed the study. As the subjects acted as their own controls, of the enrolled 
subjects only those who completed the study were included in the statistical 
analyses. In addition to the 10 women who discontinued, one woman had a 
persisting follicular-like structure from the first monitoring. Her data was 
therefore removed, leaving a total of 114 eligible subjects for analyses. The 
disposition of the subjects, with reasons for premature discontinuation, is 
illustrated in Figure 3.  
 
Adverse events leading to premature discontinuation in two women in study I 
comprised one case of massive vaginal bleeding lasting one day during the use 
of monophasic gestodene pill (the subject discontinued after 56 days) and mood 
changes in a woman on triphasic gestodene pill (withdrew from the study after 
23 days). In studies III & IV, mood changes and swelling led to a premature 
discontinuation of one woman after 30 days' use of monophasic gestodene pill, 
and another woman using monophasic gestodene pill discontinued her 
participation in the study after two months because of deep venous thrombosis.  
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Figure 3 Disposition of the subjects 
 
The volunteers were either regular visitors of the participant clinics or they were 
recruited by way of a newspaper advertisement. Very similar eligibility criteria 
were used in all studies. Volunteer subjects were to be 18 to 35 years old, 
generally healthy, showing no abnormalities in physical or gynecological 
examinations, or in the cervical smear preceding study enrollment. The women 
d id  no t re tu rn  to  c lin ic  (1)
c rite ria  o f o vu latio n n o t fu lfilled  (2)
1 0  w ith dra w a ls:
a d ve rse  e ve n ts (4 ), p e rs iste n t fo llic le  (3 ),
w e n t a b roa d  (2 ), d iff icu lty tak in g b lo od  (1)
p e rs iste n t fo llic le  fro m  th e  firs t m on ito rin g  (1)
Tota l analyzed
114
Tota l com ple ted
115
Tota l enrolled
125
Tota l recruited
128
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must have had regular spontaneous menstrual cycles of 21–32 days, and no 
absolute contraindications for combined oral contraceptive use. In study I only 
women with confirmed ovulation in one spontaneous cycle before admission 
were enrolled. Ovulation was documented by elevated serum progesterone 
levels (>15 nmol/L) during the mid-luteal phase (days 19−23).  
 
Smoking was allowed only in study I, whereas hemoglobin concentration within 
the normal range was a prerequisite for participation in studies II–IV. Breast-
feeding was an exclusion criterion in all studies and pregnancy was excluded 
prior to study admission either by a pregnancy test or on the basis of menstrual 
and contraceptive history and the result of a gynecological examination. In all 
studies the subjects were provided (free of charge) with condoms for their 
contraception during specified periods of studies when the contraceptive efficacy 
of the pills was potentially compromised. 
 
Characteristics of the subjects are shown in Table 6 for those who completed 
the present study. In study I, despite randomization, a statistically significant 
difference was seen with regard to body mass index (BMI; kg/m2) between the 
triphasic gestodene (TG) and monophasic desogestrel (MD) groups. However, 
this did not affect either follicular growth over 13 mm in diameter, or serum 
estradiol levels. 
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Table 6 Subjects, study designs, methods and main outcomes in the original publications. Data are shown as means ± SD. 
Original 
publication 
I II III  IV  
Study design phase IV, open randomized, 
comparative, parallel-group, 
multi-center  
phase IV, open  
non-randomized,  
single-group, 
pharmacodynamic  
phase IV, open  
randomized, 
intra-individual cross-over, 
pharmacokinetic comparison 
phase IV, open  
randomized, 
intra-individual cross-over,  
pharmacodynamic comparison 
Study duration 3 cycles 
 
2 cycles 4+4 cycles 4+4 cycles 
Purpose of the 
study 
To assess ovulation risk during 
and after 7-day and 10-day pill-
free periods 
To assess ovulation risk of a 
predetermined sized follicle 
To determine bioavailability of 
GEST and NET after 
interruption of EHC  
To assess ovulation risk after 
interruption of EHC 
No. of subjects 
by treatment 
n=34 MG  
n=34 TG 
n=30 MD 
n=5 Harmonet®   
 
n=11 Minulet® + Econ/30® 
 
n=11 Minulet® + Econ/30® 
 
Age (years) MG 26.8 ± 4.2 
TG  26.7 ± 4.7 
MD 26.3 ± 4.4 
23.6 ± 5.0  26.5 ± 5.1 26.5 ± 5.1 
BMI (kg/m2) MG 21.7 ± 2.2 
TG  21.5 ± 3.0‡ 
MD 23.1 ± 3.9‡ 
22.1 ± 1.7 22.7 ± 3.0 22.7 ± 3.0 
Main methods Hormone assays, 
US scanning of ovaries  
Hormone assays, 
US scanning of ovaries, 
GnRH stimulation test 
Hormone assays,  
US scanning of ovaries, 
Oral activated charcoal  
Hormone assays, 
US scanning of ovaries, 
Oral activated charcoal 
Main variables  S-FSH,  
S-Estradiol,  
S-Progesterone,  
Follicle diameter 
S-FSH, S-LH,  
S-Estradiol,  
S-Progesterone, 
Follicle diameter 
S-GEST, S-NET: 
AUC24, Cmax, tmax 
S-FSH, S-LH,  
S-Estradiol,  
S-Progesterone,  
Follicle diameter 
Main results No ovulation, 
one LUF 
4/5 women ovulated, 
one LUF 
No reduction in bioavailability 
of GEST or NET 
No ovulation 
MG = monophasic gestodene (Minulet®), TG = triphasic gestodene (Tri-Minulet®), MD = monophasic desogestrel (Mercilon®), EHC = enterohepatic circulation,  
US = ultrasonography, LUF = luteinized unruptured follicle, GEST = gestodene, NET = norethisterone, ‡ Significant difference (p=0.045) 
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2 ETHICAL CONSIDERATIONS 
 
The local Ethics Committees approved the protocols and details regarding 
informed consent before the studies, and the studies were conducted in 
accordance with the ethical principles of the Helsinki declaration. 
 
Prior to the studies, the volunteers gave signed informed consent, after being 
informed about the nature and requirements as well as the benefits and potential 
risks of the studies. 
 
 
3 STUDY TREATMENTS 
 
In study I the volunteers were randomly allocated to receive one of the following 
three preparations: 
 
1. Minulet® (Wyeth-Ayerst Laboratories, St. David’s, Pa):  
75 µg GEST and 30 µg EE2 in each pill (referred to also as ‘MG’); 
2. Tri-Minulet® (Wyeth-Ayerst Laboratories, St. David’s, Pa):   
50 µg   GEST and 30 µg EE2  (6 days) 
70 µg   GEST and 40 µg EE2 (5 days) 
100 µg GEST and 30 µg EE2  (10 days) (referred to also as ‘TG’); 
3. Mercilon® (NV Organon, Oss, The Netherlands):  
150 µg desogestrel and 20 µg EE2 in each pill (referred to also as ‘MD’). 
 
The above-mentioned OC preparations, as well as Harmonet® (75 µg GEST and 
20 µg EE2 ; Wyeth Medica Ireland, Co. Kildare, Ireland) in study II and Minulet®  
(Wyeth Medica Ireland, Co. Kildare, Ireland) in studies III & IV were supplied by 
Wyeth. 
 
GnRH-analog (Suprefact®, Hoechst, Switzerland) in study II, and Econ/30® pills 
(1 mg NET Ac and 30 µg EE2; Orion, Helsinki, Finland) and activated charcoal 
(Carbo medicinalis®; Leiras Oy, Turku, Finland) in studies III & IV were 
purchased as commercially available packages.  
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4 CONCOMITANT MEDICATION 
 
Chronic use of steroids and antibiotics and the use of estrogens and 
progestogens other than study medication was prohibited throughout study I. In 
study II the volunteer women agreed not to use any medication apart from the 
study drugs. In studies III & IV women using any drug known to interfere with the 
pharmacokinetics of pill steroids were excluded from participation. Such 
medication included injected or implanted estrogens, progestogens or 
androgens within the previous 6 months, CYP-enzyme inhibitors or inducing 
agents, broad-spectrum antibiotics and other substances which could affect the 
enterohepatic cycling of steroids.  
 
 
5 ULTRASONOGRAPHY 
 
In the present study, to detect follicular growth, the two largest follicles in any 
ovary were scanned in two dimensions and for both follicles the mean of these 
two measures was taken. An intravaginal probe (6.5 MHz, Hitachi EUB-405E; 
Hitachi Medical Corporation, Tokyo, Japan) was used at the Family Planning 
Clinic of the Family Federation of Finland in all studies. In the other two clinics, 
in study I intravaginal probes of 6–7 MHz were used. 
 
 
6 DETERMINATION OF OVULATION 
 
During the treatment period of study I, a serum progesterone concentration 
exceeding 9.6 nmol/L plus follicle rupture was considered to represent ovulation, 
this being used in studies by the Population Council. In studies II–IV follicular 
growth beyond 13 mm plus its rupture, and serum progesterone concentrations 
of >5 nmol/L were used to indicate ovulation (Hoogland and Skouby, 1993), as 
shown in Table 2.  
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7 SAMPLE HANDLING AND HORMONE ASSAYS 
 
In all studies blood samples were collected by antecubital phlebotomy. 
However, in study III, during the days when frequent samples were collected for 
determination of pharmacokinetic parameters, blood was drawn via an 
intravenous catheter fitted in a forearm. Blood was allowed to clot at room 
temperature and then centrifuged; serum was separated and stored at -20°C 
until assayed. The serum samples were all analyzed simultaneously at the end 
of the study, with all samples from the same subject and for the same hormone 
being analyzed in the same assay in order to avoid inter-assay variation. Details 
of the hormone assays used are given in Table 7. 
43  
Table 7  Characteristics of hormone assays 
Analyte Method Intra-assay  
CV% 
Inter-assay  
CV% 
Practical 
detection 
 limit 
Laboratory Study 
Estradiol RIA1 
RIA2 
IFMA3  
5.0-7.3 
4.3 
3.8-10.0 
10.4-16.6 
7.9 
3.6-9.7 
55 pmol/L 
75 pmol/L 
50 pmol/L 
STRL  
NIJ, LEU  
FFF 
I, IV 
I 
II 
Progesterone IFMA3 
 
RIA2 
3.3-7.3 
 
4.1 
2.7-10.1 
 
9.1 
0.8 nmol/L 
 
1.3 nmol/L 
STRL 
FFF 
NIJ, LEU  
I, IV 
II 
I 
FSH IFMA3 
 
IRMA4 
3.0-4.8 
 
3.3-5.5 
3.7-4.3 
 
6.3-7.6 
0.05 IU/L 
 
0.60 IU/L 
STRL 
FFF  
NIJ, LEU  
I, IV 
II 
I 
LH IFMA3 3.7-4.7 2.4-7.5 0.05 IU/L FFF  
STRL 
II 
IV 
GEST RIA5 5.5-7.3 7.6-11.7 0.3 nmol/L STRL III 
NET RIA1 6.3-9.9 8.5-17.2 0.3 nmol/L STRL III 
 
 
1Modified according to Sufi et al., 1991, 2Modified according to Thomas et al., 1977, 3Delfia®, 4Described in Kremer et al., 1991,  
5Modified according to Nieuweboer et al., 1989 
STRL=Steroid Research Laboratory, Institute of Biomedicine, University of Helsinki, Helsinki, Finland; 
FFF = Family Federation of Finland, Helsinki, Finland;  
NIJ = Reproductive Endocrinology Laboratory, University Hospital of Nijmegen, Nijmegen, The Netherlands;  
LEU = University Hospital of Gasthuisberg, Leuven, Belgium. 
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8 STATISTICAL ANALYSIS 
 
In study I the sample size estimate was made on the basis of the proportions of 
women who developed follicles with a diameter of 18 mm or greater. The study 
was designed to detect a difference between proportions of 25% and 60% in two 
treatment groups with 80% power, using 2-sided tests. Accordingly, 35 women 
were enrolled to ensure that 30 could be evaluated in each treatment group (i.e., 
105 enrolled to ensure 90 for evaluation in total). Comparison between the MG, 
TG, and MD groups regarding the largest follicle and subject demographics was 
carried out by 1-way analysis of variance. Concentrations of FSH and estradiol 
were analyzed by analysis of variance for repeated measurements. Differences 
between means were compared pair-wise by linear contrast within the analysis 
of variance model. 
 
In studies III and IV all the analyses were performed as 2-sided tests. For all 
continuous variables the assumption of normality was checked by examining the 
residuals. Analyses were carried out both with and without the extreme 
observations (outliers) if the assumptions of normality were not fulfilled. If the 
results of statistical tests were similar with and without the extreme observations, 
results with all observations are reported; otherwise results of both analyses are 
reported.  
 
In study III, for AUC0-24h, Cmax and tmax, paired t-tests were used to analyze the 
difference between charcoal and control cycles for each pill. The difference from 
control cycle to charcoal cycle between the 2 pills was tested using analysis of 
variance for a cross-over design.  
 
In study IV, for LH, FSH, estradiol and the diameter of the leading follicle, 
individual mean values from each period of one week (days 1–7, 8–14, 15–21 
and 22–28) were used as outcome variables. Analysis of variance for repeated 
measurements was used to test the difference between the charcoal and control 
cycles, separately for each pill (NET Ac and GEST). The difference in the control 
cycle vs. the charcoal cycle between the two pills was tested using analysis of 
variance for a cross-over design with repeated measurements within periods.  
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All statistical analyses were carried out with SAS software (SAS Institute Inc., 
version 6.12, Gary, NC, USA). A p-value less than 0.05 was considered 
statistically significant.  
 
 
9 RECORDING COMPLIANCE  
 
Diaries were supplied in order to mark down pill intake, as well as the 
occurrence of spotting, bleeding and possible concomitant medication. In 
studies II–IV, exact times of pill taking were also recorded. 
 
In order to decrease unintended pill omissions, in study II the pill was ingested, 
when scheduled, under an investigator’s supervision on those days when the 
women came to the clinic for follow-up visits.  
 
In studies III & IV the pill was ingested under the investigator’s supervision 
during the most critical days, i.e. on days 13, 14 and 15 in both the control and 
charcoal treatment cycles during the use of both pills (NET Ac and GEST).  
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V RESULTS 
 
1 RECOVERY OF THE PITUITARY-OVARIAN AXIS DURING 
AND AFTER THE PILL-FREE PERIOD 
 
1.1 Extension of the pill-free period to ten days (Study I) 
 
Mean serum estradiol concentrations during and after the standard 7-day pill-
free period are illustrated in Figure 4a and those during and after the extended 
pill-free period in Figure 4b. The respective serum FSH levels are shown in 
Figures 4c and 4d.  
 
In most women, serum FSH concentrations rose to levels normally seen in the 
late follicular phase as soon as the end of the first pill-free week (Figure 4c). This 
indicates rapid restoration of pituitary activity after stopping OCs. When the pill-
free period was extended beyond 7 days, no further increase in serum FSH 
levels was seen. This is clearly illustrated in Figure 4d. In fact, despite three 
more days without pills, serum FSH concentrations started to decrease after the 
first 7 pill-free days, suggesting the possibility of a negative feedback effect to 
the excretion of endogenous estradiol.  
 
In the comparison of three different OC preparations, namely monophasic GEST 
(MG), triphasic GEST (TG) and monophasic DSG (MD), the MG preparation 
seemed to suppress pituitary function most effectively during and after the 
standard 7-day pill-free interval (Figure 4c). The overall mean serum FSH 
concentrations were statistically significantly lower in the MG group than in the 
TG (p=0.03) and MD groups (p=0.03). During and after the extended pill-free 
period of 10 days (Figure 4d) no difference was seen between the two 
monophasic preparations, whereas the mean FSH levels associated with TG 
pills were higher than in women using the MG preparation (p=0.02) and those in 
the MD group, even though the latter difference was nonsignificant (p=0.05). 
However, after resuming the pills, pituitary function was rapidly suppressed 
again with all three treatments, both after the standard pill-free period of 7 days 
and after the extended pill-free period (Figures 4c and 4d).  
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After stopping OCs, serum estradiol concentrations started to increase, but 
considerable intersubject variation was seen, during and after the 7- and 10-day 
pill-free periods. This indicates great variability in both degree of ovarian activity 
as well as in timing of restoration of ovarian function after stopping pill intake. 
However, estradiol levels were consistently higher when the pill-free period was 
extended to 10 days (Figure 4b), compared with the standard pill cycle with a 7-
day pill-free period (Figure 4a). 
 
As shown in Figure 4a, the overall mean serum estradiol levels were higher in 
women using the MD preparation than in women in the other two groups, during 
and after the 7-day pill-free period (MD vs. MG p=0.01; MD vs. TG p=0.01). 
After the 7-day pill-free period, when the pills were restarted, mean serum 
estradiol levels decreased with all OC preparations, although this was more 
pronounced as regards pills containing GEST (Figure 4a). During and after the 
10 pill-free days (Figure 4b), women in the MD group showed higher serum 
estradiol concentrations, compared with women using TG pills (p=0.01). Despite 
reintroduction of OCs, serum estradiol levels continued to increase in the MD 
group, whereas they remained virtually unchanged in women using MG or TG 
pills (Figure 4b). Subjects in the MG and TG groups did not differ from each 
other in either of the monitoring periods.  
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Figure 4 Mean serum estradiol (a and b) and FSH (c and d) concentrations during 
and after the standard 7-day pill-free period (study period 1) and when 
the pill-free period was extended to 10 days (study period 2) in women 
using 1 of 3 OC preparations 
 
 
1.2 Extension of the pill-free period until the leading follicle had reached a 
diameter of 16 mm (Study II) 
 
In 5 women using an OC preparation consisting of 75 µg of GEST and 20 µg of 
EE2 (Harmonet®) the pituitary gland was well suppressed at the end of the 
regular OC cycle, as indicated by very low serum concentrations of FSH and LH 
on day 21 (Figures 6a and 6b, respectively). Consistently with the results from 
study I, serum FSH concentrations rose to the level normally seen in the late 
follicular phase of the cycle as early as the end of the normal 7-day pill-free 
period (data not shown). The mean concentration of serum LH had also clearly 
increased by pill-free day 7 but it continued to rise for a couple of days to reach 
its late follicular phase level. Figure 6c illustrates wide intersubject variation in 
the concentrations of serum estradiol.  
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2 FOLLICULAR GROWTH AND OVULATION 
 
2.1 Extension of the pill-free period to ten days (Study I) 
 
In study I no ovulation was seen in any of the three regimens, either during or 
after the standard 7-day pill-free period or when the pill-free period was 
extended by three days, as judged by serum progesterone levels of <9.6 nmol/L 
and by absence of rupture of the leading follicle.  
 
However, during and after the 7-day pill-free period, 14% of the subjects showed 
a follicle greater than 13 mm. Follicles exceeded a diameter of 13 mm in 9%, 
6% and 27% of the women in the MG, TG and MD groups, respectively, 
whereas only two women developed a follicle of 18 mm or greater after the 
regular pill-free period of 7 days. Both belonged in the MD group, representing 
6.7% of women in that group.   
 
When the pill-free period was extended to 10 days, in 53% of the women 
follicles grew beyond 13 mm, in 41% of MG users, 47% of TG users, and in 70% 
of MD users. A preovulatory follicle of >18 mm occurred in a total of 29% of the 
women after the 10-day pill-free period (in 24% of both MG and TG pill users, 
and in 40% of MD users).  
 
There were three more women (1 in the TG group and 2 in the MD group) who 
showed follicular growth beyond 13 mm during or after the 7-day pill-free period. 
However, they were withdrawn from the study prior to when it was decided that 
women with a persisting follicle were allowed to continue in the study. Thus, 
these women were not included in the statistical analysis. One more woman 
was not included in the statistical analysis, as she already had a persisting 
follicle-like structure of 45 mm in diameter at the first monitoring. 
 
As illustrated in Figure 5, follicles became largest in women using the MD 
preparation. The difference was statistically significant between the MG and MD 
groups (p<0.022) and between the TG and MD groups (p<0.001) during and 
after the 7-day pill-free period. After deliberate omission of 10 pills the mean 
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maximal follicle size in the MD group was statistically significantly greater than in 
the MG group (p=0.015).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Mean (±SD) maximal diameters of follicles during and after the 7-day 
pill-free period (study period 1) and the 10-day pill-free period (study 
period 2) in women using 1 of 3 combined oral contraceptive 
preparations (* p<0.05; *** p<0.001). 
 
  
 
2.2 Extension of the pill-free period until the leading follicle had reached a 
diameter of 16 mm (Study II) 
 
When the pill-free period was deliberately extended until the leading follicle 
reached a diameter of 16 mm, four of five women ovulated. For four women it 
took 14 to 22 days to grow a follicle of 16 mm in diameter, after stopping the 
previous pill pack (day 21). The mean (±SD) serum FSH, LH, estradiol and 
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progesterone concentrations in the four ovulating women are shown in Figures 
6a, b, c and d, respectively. As indicated in Figures 6a and 6b, in all women both 
FSH and LH surges occurred soon after the pills were restarted on day 1. The 
mean maximum serum LH concentration was 23.5 IU/L.  
 
Individual maximum serum progesterone concentrations (Figure 6d) in the 4 
ovulating women ranged between 10.7–23.0 nmol/L (mean 15.6 nmol/L).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 Mean (±SD) serum concentrations of (a) FSH, (b) LH, (c) estradiol and 
(d) progesterone in four ovulating women in study II during the 
extended pill-free period, and in a subsequent cycle starting on day 1 
(follicle diameter = 16 mm). Day 21 represents the last pill-taking day of 
the previous contraceptive cycle. 
 
An intravenous injection of GnRH analog was given on the third day (day 3) after 
reintroduction of the pills. In one woman an LH surge and rupture of a follicle 
took place just before GnRH administration (early morning of the same day), 
and in three ovulating women the peak concentration of serum LH was 
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measured within 24 hours after the intravenous bolus of GnRH. However, in 
these three women also, serum LH levels had started to increase before the 
GnRH bolus, as indicated by a 30% increase in the mean concentration of three 
consecutive LH samples in the midfollicular phase of the cycle (Yen, 1991). This 
suggests spontaneous onset of a preovulatory LH surge (Figure 6b).  
 
The dominant follicles of four ovulating women ruptured at a mean size of 20.7 
mm. Ovulation occurred 2 to 7 days after reintroduction of OCs, i.e. 0 to 5 days 
after the i.v. GnRH bolus. Development of the leading follicle in each ovulating 
woman is shown in Figure 7. 
 
Although the criteria of ovulation (Hoogland and Skouby, 1993) were fulfilled in 
study II, ovulation did not seem to be completely ‘normal’ in any of the four 
women. In one woman a follicle ruptured as late as 4 days after the LH peak 
and 5 days after the intravenous bolus of GnRH analog. The maximum serum 
progesterone concentration in this woman was 15.0 nmol/L. Furthermore, in all 
four ovulating women the overall serum progesterone levels remained well 
below those seen in normal ovulatory cycles, and no preovulatory rise in 
progesterone levels was seen in any woman (Figure 6d). 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 Follicle diameter in four ovulating women. Day 1 is the first day of the 
new pill pack. GnRH analog was given on Day 3. 
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3 LUTEINIZED UNRUPTURED FOLLICLES 
 
In study I, serum progesterone levels remained under 9.0 nmol/L in all cases, 
except for one woman in the MG group who showed signs of a luteinized 
unruptured follicle (LUF). Her serum progesterone level had increased sharply to 
21.9 nmol/L on treatment day 3, after the extended pill-free period. On the same 
day a follicle of 12 mm in diameter was measured, and it grew to a size of 21 
mm by pill cycle day 7. By then, the serum progesterone concentration had 
dropped well below the ovulatory level (2.2 nmol/L), and thereafter the follicle 
diminished gradually without rupturing. The highest measured estradiol level 
was only 319 pmol/L throughout monitoring.  
In study II one woman had signs consistent with a luteinized unruptured follicle. 
Also with her, steep increases in the serum concentrations of both FSH and LH 
were seen after the reintroduction of an OC. A dominant follicle reached a 
diameter of 16 mm as late as after 26 pill-free days, and it was accompanied by 
a normal preovulatory estradiol level of 920 pmol/L. The highest progesterone 
concentration throughout the observation period was only 5.8 nmol/L and the 
dominant follicle diminished in size without rupturing, after it had reached a 
diameter of 31.2 mm.  
 
 
4 INTERRUPTION OF ENTEROHEPATIC RECIRCULATION 
OF NORETHISTERONE AND GESTODENE BY CHARCOAL 
TREATMENT  
 
4.1 Bioavailability of norethisterone and gestodene (Study III) 
 
The bioavailability of NET and GEST was evaluated in 11 women using either a 
preparation containing 75 µg GEST and 30 µg EE2 (GEST pills) or 1 mg NET Ac 
and 30 µg EE2 (NET Ac pills) for four months and thereafter the other treatment 
for 4 subsequent months. More specifically, Cmax, tmax and AUC0-24h were 
measured for NET and GEST after repeated ingestion of activated charcoal in 
mid-cycle, and during the regular cycle serving as a control.  
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No statistically significant differences were seen in any of the measured 
parameters between the control and charcoal cycles, with either pill or between 
the two pills (GEST pills and NET Ac pills). The mean AUC0-24h ±SD for GEST 
during the control cycle was 547 ± 384 nmol×h/L compared with 544 ± 292 
nmol×h/L in the charcoal cycle (p=0.95). During the use of NET Ac pills the 
respective values for NET in the control and charcoal cycles were 604 ± 261 
nmol×h/L and 540 ± 244 nmol×h/L (p=0.15).  
 
Mean serum GEST and NET concentrations during 24 hours are shown in 
Figures 8 and 9, respectively. The mean (±SD) Cmax values of GEST in the 
control and charcoal cycles were comparable, 42.4 ± 20.6 nmol/L and 40.2 ± 
18.0 nmol/L, respectively (p=0.25). The maximum concentration of GEST was 
reached in both the control and charcoal cycles within 110 min (mean tmax ± SD 
was 82 ± 34 min in the control GEST pill cycle and 95 ± 35 min in the charcoal 
GEST pill cycle). Neither was a difference seen in the mean Cmax values of NET 
between cycles. The mean (± SD) maximum concentration was 75.4 ± 29.0 
nmol/L in the control cycle and 69.7 ± 28.0 nmol/L in the charcoal cycle 
(p=0.32). Tmax (mean ± SD) for NET was 124 ± 39 min in the control cycle 
(range 60–120 min) and 124 ± 60 min in the charcoal cycle (range 60–180 min). 
When the difference from the control cycle to the charcoal cycle between the 
two pills was tested, utilizing AUC0-24h and Cmax values calculated in the control 
and charcoal cycles of each pill treatment, no difference between GEST and 
NET was seen (for AUC0-24h p=0.29 and for Cmax p=0.42). In other words, 
activated charcoal did not have a different effect on the bioavailability of the two 
progestogens. 
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Figure 8 24-h mean (± SD) serum gestodene concentrations during the regular 
contraceptive cycle and during the cycle with charcoal treatment in 
women using a monophasic gestodene preparation (75 µg GEST and 30 
µg EE2). 
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Figure 9 24-h mean (± SD) norethisterone concentrations during the regular 
contraceptive cycle and during the cycle with charcoal treatment in 
women using a monophasic norethisterone acetate preparation (1 mg 
NET Ac and 30 µg EE2) 
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4.2 Charcoal treatment and risk of ovulation (Study IV) 
 
No ovulation was detected in 11 women under either OC treatment (GEST or 
NET Ac pills), whether charcoal was given or not. Serum progesterone 
concentrations in all women remained well under the ovulatory level (<3 nmol/L, 
data not shown). Follicles also remained small in all cases but two. One subject 
developed a preovulatory sized follicle during both the control and charcoal 
treatment cycle of NET Ac pill use, whereas in the other subject follicles grew 
beyond 13 mm in diameter during the control and charcoal treatment cycles of 
both pill regimens. A clear increase in serum estradiol concentrations was seen 
in both women, but no rupture of follicles was detected.  
 
Activated charcoal treatment did not seem to affect pituitary-ovarian function 
associated with either pill treatment, as evaluated by measurements of LH, FSH 
and estradiol concentrations and the diameter of the leading follicle. Neither was 
a different effect seen between the two pills.  
 
With either pill, when control and charcoal treatment cycles were compared, no 
statistically significant differences were seen in the mean serum concentrations 
of LH (GEST p=0.58; NET p=0.33), FSH (GEST p=0.40; NET p=0.06) or 
estradiol (GEST p=0.36; NET p=0.37), or in the mean diameter of the leading 
follicle (GEST p=0.57; NET p=0.27). When each week (days 1–7 = week 1, 
days 8–14 = week 2, days 15–21 = week 3 and days 22–28 = week 4) of the 
control and charcoal treatment cycles was compared, with either pill, no 
statistically significant differences were detected in any of the measurements. 
  
Differences in the mean serum concentrations of LH, FSH and estradiol, and the 
mean diameter of the leading follicle from the control to the charcoal treatment 
cycles were compared between GEST and NET Ac pill treatments on a weekly 
basis. No statistically significant differences appeared in this analysis with regard 
to any of the measured parameters (p-values for LH, FSH, estradiol and follicle 
diameter were 0.33, 0.09, 0.69 and 0.76, respectively).  
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In addition, the time-effect was not statistically significantly different between the 
two pill treatments as regards LH (p=0.13), estradiol (p=0.23), or the mean 
diameter of the leading follicle (p=0.92). In the cross-over analysis FSH 
concentrations showed a significant difference in the treatment vs. time 
interaction (p=0.02), although not when the highest FSH value of 14.5 IU/l in one 
subject was excluded (p=0.05). 
 
 
5 COMPLIANCE IN PILL TAKING 
 
In addition to the intended pill omissions for 3 consecutive days in study I, four 
subjects accidentally forgot 1 pill and 1 subject forgot 2 pills within 7 days after 
the 10-day pill-free period. Moreover, two subjects omitted one pill during the 
first pill-taking week after the standard 7-day pill-free period in study I. These 
subjects were, however, included in the statistical analysis, as these further 
omissions did not affect the subjects’ individual hormone profiles, overall 
follicular growth or increase in serum estradiol levels.  
 
The most critical parts of studies II–IV were secure with regard to pill taking. In 
study II no additional pill omissions were reported. In studies III and IV one 
subject missed one pill (pill number 17 in the first NET Ac pill cycle), and another 
woman reported four 24-hour late pills (one in the second NET Ac pill cycle, 2 
pills in the second GEST pill cycle and one, pill number 18, in the third GEST 
cycle). Moreover, six women reported 2- to 10-hour late pills a total of 32 times. 
In none of these cases was the timing of missed or late pills critical in terms of 
the measurements performed in studies II–IV. 
 
 
6 CONCOMITANT MEDICATION  
 
Five women used either penicillin or tetracycline or their derivatives for 7 to 10 
days in study I. In two women using these antibiotics during the control pill cycle, 
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follicular development and elevated serum estradiol levels were demonstrated 
after the extended pill-free period. In these two cases it is unlikely that the 
antibiotic would have influenced ovarian activity over one completely 
suppressed cycle. Enlarged follicles were detected after the extended pill-free 
period in one woman who had used a penicillin derivative during and after the 7-
day pill-free interval. Even though unlikely, we cannot rule out the possibility that 
the follicular activity seen was influenced by concurrent medication. No follicular 
activity was detected in two of the 5 women. 
 
In studies II–IV none of the women reported the use of any concomitant 
treatment known to interfere with steroid metabolism. 
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VI DISCUSSION 
 
The failure rate of the combined oral contraceptive method, when used correctly, 
is considered to be very low, the Pearl index being only 0.1 pregnancies per 100 
woman-years (Hatcher et al., 1994). Under the circumstances of user failure, for 
various reasons, the Pearl index for OCs may increase to 0.5–5 per 100 
woman-years, with great variability between different populations (Potter, 1996). 
Failure is generally thought to be associated with missed or late pills, 
gastrointestinal upsets or interaction with other drugs. Therefore, in the present 
study, conditions simulating these circumstances were created. However, only 4 
women ovulated, all after deliberate omission of at least 14 consecutive pills and 
when pills were restarted at the stage when the diameter of a dominant follicle 
had reached 16 mm.  
 
Ovulation and possible pregnancy during pill intake can only occur when 
residual ovarian activity appears and further follicular maturation and a mid-cycle 
LH surge is allowed. Besides ovulation prevention, OCs also have a number of 
other contraceptive effects which may or may not persist in the case of escape 
ovulation. In a few clinical studies, in which cervical mucus has also been 
investigated in connection with deliberate pill omission, the mucus has remained 
‘hostile’ despite measurable ovarian activity (Chowdhury et al., 1980; Hamilton 
and Hoogland, 1989; Killick et al., 1990; Morris et al., 1979; Spona et al., 1993). 
However, adjunctive actions such as this may be least effective at the end of the 
pill-free period, when restoration of ovarian activity is also anticipated 
(Guillebaud, 1981). Moreover, in cases of accidental pregnancy in women using 
OCs, these adjunctive mechanisms of action are clearly insufficient. Hence, to 
ensure efficacy of an OC, inhibition of pituitary FSH, which promotes follicular 
growth and maturation, should be as complete as possible.  
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1 OC REGIMENS AND THEIR POTENCY TO INHIBIT 
OVULATION 
 
It is well known that the pituitary is not completely suppressed even with old 
preparations containing 50 µg of EE2 (Elstein et al., 1974). Hence, it is surprising 
that contraceptive efficacy does not seem to be appreciably compromised 
during regular use of OCs containing only 20 µg of EE2, when combined with 
traditional doses of gestodene (75 µg) or desogestrel (150 µg) and when the 
pills are taken regularly (Crosignani et al., 1996; Endrikat et al., 1995; Endrikat et 
al., 1997; Endrikat et al., 2001; Fitzgerald et al., 1994; Rosenberg et al., 1999; 
Spona et al., 1996a; van Heusden and Fauser, 1999). However, little is known 
about ovulation inhibition potency of low-dose and ultra low-dose regimens, 
when compliance is poor.  
 
In this study a combination of 150 µg of desogestrel and 20 µg of EE2 resulted in 
less ovarian suppression during and after the 10-day pill-free period, compared 
with gestodene preparations with at least 30 µg EE2 per day. Whether this is due 
to the lower dose of EE2, or a different progestogen component, or both, cannot 
be proven, as no control was used as regards the same progestogen 
component, and dose. From earlier studies there is no agreement on the relative 
importance of an EE2 dose compared with a progestogen component in 
inhibition of residual ovarian activity (Fitzgerald et al., 1994; Mall-Haefeli, 1991; 
Römmler et al., 1985; van Heusden and Frauser, 1999).  
 
Because there is a great deal of evidence indicating that OCs are reliable and 
safe, new research is concentrated on ultra-low dose regimens, to further 
minimize unfavorable effects, rather than investigation of underlying 
mechanisms of action, such as regulation of the hypothalamus-pituitary-ovarian 
axis. It is believed that in OCs progestogen prevents the mid-cycle LH surge, 
whereas pituitary inhibition of FSH release is probably caused by both EE2 and 
progestogen, the overall effect being synergistic (Mishell et al., 1977, Römmler 
et al., 1985). Hence, interaction between synthetic OC steroids and pituitary 
gonadotropins may be more complex than might be interpreted from the sum of 
progestogenic and estrogenic components of the regimen.  
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Newer progestogens not only differ greatly in their structure, but they show 
considerable differences in their pharmacokinetics and dose-effect responses 
(Kuhnz and Gieschen, 1998). Furthermore, EE2 may express its inhibitory effect 
at the pituitary only within a certain dose range. Thus, a regimen with a 
biologically potent progestogen, such as gestodene, may suppress pituitary-
ovarian function effectively when combined with only 15 µg EE2  (Gestodene 
Study Group 322, 1999), but this may not apply to other progestogens with 
lesser potency to inhibit ovulation (Kuhl, 1996; Römmler et al., 1985).  
 
As follicular maturation may be initiated during the 7-day pill-free period, and in 
triphasic preparations the progestogen dose is lowest during the first phase of 
the cycle, it has been speculated that triphasic OCs may result in less complete 
pituitary-ovarian suppression than monophasic regimens. In the present study a 
similar degree of ovarian suppression was achieved with mono- and triphasic 
preparations, both containing gestodene. This is in contrast to results obtained 
mainly from some case-reports and uncontrolled studies (Caillouette and 
Koehler, 1987; Kovacs et al., 1989; Römmler et al., 1985; Smith et al., 1986; 
Van der Vange et al., 1985), and in line with results from more strictly controlled 
studies carried out in conditions of regular use of OCs (Crosignani et al., 1996; 
Gaspard et al., 1984; Grimes et al., 1994; Holt et al., 1992; Killick et al., 1990; 
Lete and Morales 1997; Spona et al., 1993; Young et al., 1992). 
 
 
2 ENTEROHEPATIC RECIRCULATION OF OC STEROIDS 
 
A substantial number of case-reports have been published on pregnancies 
occurring during the concomitant use of OCs and broad-spectrum antibiotics 
(Back et al., 1988; Bacon and Shenfield, 1980; Bainton, 1986; DeSano and 
Hurley, 1982). Hence, instructions for women on OCs persistently include a 
warning regarding concurrent therapy with broad-spectrum antibiotics, although 
scientific data from controlled studies do not support an interaction (Back et al., 
1982b; Friedman et al., 1980; Joshi et al., 1980b). Broad-spectrum antibiotics 
have been shown to interfere with the normal intestinal bacteria participating in 
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hydrolysis of steroid conjugates. This may interrupt enterohepatic recirculation of 
contraceptive steroids by preventing reabsorption of the steroids. Whether this is 
relevant with regard to progestogens or even with EE2, has still not been 
convincingly proven. Even if it occurs, its clinical importance may be negligible 
(Back et al., 1990), and certainly anecdotal case-reports do not justify any 
causal relationship. We therefore tested whether repeated ingestion of activated 
charcoal on three consecutive days would affect the bioavailability of two 
progestogens, norethisterone and gestodene, and whether it impaired pituitary-
ovarian suppression under two different OC regimens. The circumstances 
created also simulated conditions where enterohepatic recirculation of 
contraceptive steroids would be affected by treatment with broad-spectrum 
antibiotics, or by gastroenteritis. Even though pill omissions at mid-cycle are 
anticipated to confer less risk of contraceptive failure than extended pill-free 
intervals (Guillebaud, 1987; Molloy et al., 1985), charcoal was administered at 
mid-cycle, as the risk of ovulation had been already elucidated during and after 
the pill-free period.  
 
As activated charcoal did not alter any of the pharmacokinetic parameters, 
compared with non-charcoal treatment cycles, it can be concluded that 
enterohepatic recirculation does not occur with these two progestogens to such 
an extent that it would be of any clinical importance. Although two women 
showed follicular maturation and growth beyond a diameter of 13 mm, it is 
unlikely that charcoal would have had any influence, as in both women follicles 
developed in both the charcoal and control cycles. No ovulation occurred in 
connection with either pill, regardless of the administration of activated charcoal. 
 
Even though the study set-up did not reflect exactly the situation in 
gastroenteritis, which involves inflammation of the intestinal wall (Adlercreutz et 
al., 1979), it is considered that disturbance of enterohepatic circulation would 
have been demonstrated if it is of importance. This is because the dosage of 
activated charcoal used in the present study has been previously shown to be 
effective in a study on mifepristone (Heikinheimo et al., 1989) and it was double 
the dose used in the treatment of diarrhea. Nevertheless, there may be a group 
of women, slow metabolizers, in whom there is no hydroxylation and who are 
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thus more dependent on enterohepatic recirculation of steroids. It is most likely, 
however, that many of the pill failures in women using OCs and broad-spectrum 
antibiotics concurrently are due to noncompliance in pill taking. 
 
 
3      MISSING PILLS – AN INHERENT PROBLEM WITH OCS 
 
Noncompliance as regards missed or late pills is an inherent problem with OCs 
in both clinical studies that aim at elucidating the problem as well as in clinical 
practice. In a large proportion of women in the present study, additional missed 
or late pills could not be reliably recorded and eliminated. However, the risk of 
drawing the wrong conclusions concerning ovulation and pill omission is 
minimal, because in the particular study in which all cases of ovulation occurred, 
pill taking was closely monitored.  
 
In an earlier study on ‘reliable pill takers’, more than a third of the women who 
experienced an accidental pregnancy during OC use did not report any known 
predisposing factor (Sparrow, 1998). It was suggested that these cases were 
due to method failure, whilst two thirds of the pregnancies could have been 
associated with predisposing factors other than noncompliance in pill taking.  
 
Even though women on pills occasionally appear to become pregnant without 
any obvious underlying reason, it is now known that missing pills is much more 
common than is generally recognized. It has been shown only recently, by using 
a reliable method involving a microchip-augmented pill dispenser, that more 
than 30% of women miss three or more pills during their first two treatment 
cycles, and during the third cycle more than 50% of users miss that number 
(Potter et al., 1996). Discrepancy between this outcome and results obtained in 
interview studies indicates that missed pills are underreported to a great extent. 
The poorest pill takers are often also those who can least well recall the number 
and timing of the missed pills (Potter, 1996).  
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4 THE PILL-FREE PERIOD AND THE RISK OF ESCAPE 
OVULATION 
 
An OC regimen of 21 pills, followed by 7 pill-free days, was initially introduced by 
doctor Gregory Pincus to mimic a regular menstrual cycle of 28 days (Fraser 
and Jansen, 1983). A monthly cycle for the first OC was, however, chosen 
arbitrarily to make the pill more acceptable at a time when oral contraception 
was still a novel concept. It was not to become mandatory, but merely to be 
developed in the next stage to allow a longer period of active medication (Rutter 
et al., 1988).  Although an OC regimen of 21 days on and 7 off offers probable 
benefits, such as a lesser total quantity of OC steroids during the 4-week period 
and, through withdrawal bleeding, a monthly check-up of not being pregnant, it 
also has a great disadvantage. The pill-free interval may not only allow 
restoration of pituitary-ovarian activity, and in many women recruitment of 
follicles, one of which will be later selected as a dominant follicle, but it may also 
lead to further pill omissions, as the pill-taking routine must be re-established 
after each period of cessation of the pills.  
 
Full pituitary recovery has been shown to take place as early as during the 
standard 7-day pill-free period, even with OCs containing 30 µg of EE2 (Killick et 
al., 1987), and the return of full contraceptive efficacy takes 7 days (Guillebaud, 
1987). Thus, the first week of pill-taking is critical for the contraceptive efficacy of 
OCs. Furthermore, it is often not realized that the pill-free period will also 
become extended if the last pills of the previous cycle are forgotten and the next 
cycle is started correctly (Guillebaud, 1987).  
 
The growth of follicles has been detected in over 50% of normal OC cycles 
(Spona et al., 1996a; Van der Vange et al., 1985). Specifically, follicles greater 
than 10 mm in diameter, the size considered a prerequisite for their further 
development, have been observed on pill-free day 7 in 18 to 27% of women 
(Tayob et al., 1990; van Heusden and Frauser, 1999), and in 9 to 37% of 
women any time of a regular cycle (Crosignani et al., 1996; Fitzgerald et al., 
1994; Hamilton and Hoogland, 1989). Preovulatory follicles of >18 mm in 
diameter have been found in roughly every third cycle, after the standard 7-day 
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pill-free period (Van der Vange et al., 1985). In accordance with these findings, 
in the present study 14% of women developed a follicle of 13 mm or larger 
during or after the 7-day pill-free period. When the pill-free period was extended 
to 10 days, 53% of the women had a follicle of 13 mm or greater, and follicular 
growth to >18 mm occurred in almost one third of the women.  
 
Even though follicles were ready for ovulation and the pituitary had already 
recovered during the first 7 pill-free days, ovulation did not occur if the pill-free 
period was extended to 10 days. Hence, the growing follicles seem to lose their 
ability to ovulate or they do not receive an adequate signal for ovulation, if the 
pills are started early enough in the growing process. On the other hand, after 
14 pill-free days or more and if preovulatory follicles had reached a diameter of 
16 mm, ovulation could not be prevented by restarting the pills. An injection of 
GnRH analog was given to detect susceptibility of the follicles to ovulate, but in 
all 5 women the LH surge had taken place before GnRH injection. This suggests 
a spontaneous start of ovulation in four women who also showed rupture of the 
leading follicle.  
 
In an earlier study HCG was administered at the stage when the leading follicle 
was 18 mm in diameter (Killick, 1989). It was concluded that ovulation could be 
induced by HCG, indicating the readiness of preovulatory follicles of that size to 
ovulate if pill omission took place. In that study, follicles were allowed to grow to 
12 mm before resuming OCs. However, in that study also, spontaneous 
ovulation cannot be excluded, as serum LH concentrations were not measured 
and serum progesterone concentrations had started to increase before HCG 
injection. In another study, 6 of 10 women ovulated during a cycle starting after 
14 days on placebo pills (Letterie, 1998). A follicle diameter of 15 to 20 mm was 
reached by the time OC pills were restarted. Consistently with results from the 
present study, the follicles ruptured at a mean size of 21 mm. 
 
There appears to be a continuing tendency to further reduce OC steroid doses 
by searching for new progestogens and combinations of progestogens and an 
estrogenic component, whilst sticking to the original idea of having hormone-free  
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days every month. A regimen of 24 active pills with lower steroid doses (60 µg 
gestodene and 15 µg EE2) allowing a shortened pill-free period of 4 days, has 
been introduced only recently. The contraceptive efficacy of this regimen has 
been shown to be comparable to that of a 21-day regimen with conventional 
doses of OC steroids (Gestodene Study Group 322, 1999; Spona et al., 1996a; 
Sullivan et al., 1999). However, shortening the pill-free interval does not solve 
the problem of compliance. Continuous use of OCs for at least three months has 
been proposed previously in order to avoid withdrawal headache and to allow 
bleed-free treatment, but not to safeguard contraceptive efficacy. Replacing 
hormone-free days with placebo pills is an attempt to benefit women with poor 
compliance, but it does not offer the above-mentioned benefits.  
 
 
5 WHAT ADVICE CAN WE GIVE? 
 
There is no longer a reason to utilize the initial idea of a 28-day regimen 
including 7 hormone-free days, especially as the steroid doses are only fractions 
of the ones introduced 40 years ago. Oral contraceptives could be used for a 
minimum of three pill packs in a row to minimize 'additional' pill omissions on top 
of the 7 permitted ones. However, as long as traditional OC regimens of 21 
active days with 7 pill-free days are used, and as it is not yet possible to predict 
those women in whom pill failure can most readily occur, the present data allow 
the following considerations:  
 
The risk of ovulation is considered small if less than four pills of one pill packet 
are omitted, provided that they do not lengthen the pill-free period, they do not 
occur successively and only one of the missed pills is during the first 7 days of 
pill intake. 
 
If the first three pills of a new packet, or the last three pills of the previous packet 
have been omitted, thereby leading to an extended pill-free period of ten days, 
ovulation is unlikely to occur if no more pills are missed during the first pill-taking 
week. However, a woman should use a barrier method for one week, as it is 
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believed that after the pill-free interval, restoration of contraceptive efficacy 
occurs during the next seven days of pill taking. When the last pills of the 
previous pack have been omitted, and the seven-day pill-free period is not yet 
exceeded, a new pill pack is recommended to start without a hormone-free 
period. 
 
In the present study five women reported additional, ‘unscheduled’ pill omissions 
within seven days after the 10-day pill-free interval. However, in these particular 
cases contraceptive efficacy was not impaired, as these women did not show 
large follicles at the time of additional pill omission. There is no published data 
on the effect of cessation of pills during those seven days in circumstances 
where a preovulatory follicle exists. Neither was this investigated in the present 
study, as it would have required complicated mathematical models to exclude 
confounding factors. However, this situation is expected to be of the highest risk 
of escape ovulation. Therefore, if pills are omitted during the first 7 days of pill 
taking, preceded by a 10-day pill-free period, a hormonal emergency 
contraception should be taken and a barrier method used for one week.  
 
It is almost impossible to determine the minimum total number and exact time of 
missed pills, which would confer a significant risk of ovulation. Hence, it is safest 
to use a barrier method until the start of a next pill pack, if a total of four pills or 
more have been omitted at any time of the pill cycle. Practical advice in cases of 
pill omission is shown in Table 8. 
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Table 8 Pill omissions, risk of ovulation and use of another method of 
contraception 
 
Number of missed pills  
and preconditions 
Risk of ovulation Use of another 
method 
≤3 non-consecutive pills, 
provided that: 
• They do not include the 
first or the last pill  
• Only one pill omitted 
during the first pill-
taking week 
Very small Not needed 
The last pills of the 
previous pill pack  
Omitted 
Very small if the pill-
free interval does not 
exceed 7 days  
A new pill pack 
should be started 
immediately 
Pill-free period lengthened 
to a maximum of 10 days 
with no additional pill 
omissions during the first 7 
days of a new pack 
Small Barrier method for  
the first week of a 
new pill pack 
Pill-free period lengthened 
to a maximum of 10 days 
with additional pill 
omissions during the first 7 
days of a new pack 
Considerable Barrier method for  
the first week of a 
new pill pack and a 
hormonal emergency  
contraception 
≥4 pills at any time of a pill 
cycle 
Unpredictable Barrier method until 
the start of a new pill 
pack 
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VII CONCLUSIONS 
 
The overall results of this study indicate a high safety margin for contraceptive 
efficacy with OC regimens of 21 active pills and 7 days off, when 20 µg of EE2 or 
more is combined with 75 µg of gestodene or 150 µg of desogestrel.  
 
Follicles became most developed in the regimen consisting of 20 µg EE2 and 
150 µg desogestrel. Nevertheless, if the pill-free period is restricted to ten days 
and no additional pill omissions occur during the next week, the risk of escape 
ovulation remains small when 20 µg of EE2 or more is combined with traditional 
doses of either gestodene or desogestrel. Furthermore, both triphasic and 
monophasic gestodene preparations show a similar degree of pituitary-ovarian 
suppression when at least 30 µg of EE2 is taken daily. On the other hand, a pill-
free period of 14 days or more, accompanied by a preovulatory sized follicle of 
16 mm or more in diameter, leads ultimately to ovulation in most women. At this 
stage ovulation can no longer be prevented by restarting pills. 
 
The results of the present study did not indicate that enterohepatic recycling of 
progestogens is of any clinical significance. Thus, the present data do not 
support the current instructions to patients insisting on the use of additional 
contraceptives in the case of concurrent use of broad-spectrum antibiotics and 
OCs. Moreover, although not popular among younger women using OCs, 
charcoal treatment may be used for the treatment of diarrhea, when 
administered 3 hours or more after pill intake and at least 12 hours before the 
next pill. 
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